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3Abstract
Introduction: The primary goal in the management of intermittent claudication is to
decrease cardiovascular morbidity and mortality by disease modifying therapy. However
percutaneous transluminal angioplasty (PTA) is often performed to improve limb related
symptoms. Claudicants may have variation in symptomatology and disease progression
while awaiting PTA Moreover restenosis following PTA is a major therapeutic problem
despite high initial success rate, limiting the long-term efficacy of the procedure. There is
growing evidence that the tissue factor-tissue factor pathway inhibitor (TF-TFPI)
interaction, a major regulator of haemostasis, plays an important role in the healing
response of arteries following PTA. In this study, 1) we reassessed claudicants awaiting
femoropopliteal PTA for more than 3 months to determine changes in patient
symptomatology and disease distribution during the wait period and 2) we investigated
any association between plasma TF and TFPI concentration and the development of
restenosis following PTA.
Patients and methods: In the first part of study, 47 claudicants with a median waiting period
of 9.6 (interquartile range 4-21) months for femoro-popliteal PTA were assessed.
Assessment included symptom and co-morbidity appraisal. Arterial duplex was
performed on the symptomatic limb and compared with previous duplex study for
assessment of disease progression.
In the second part, 52 unilateral claudicants undergoing femoropopliteal PTA and 10 healthy
controls were studied for association of plasma TF and TFPI level with peripheral arterial
disease and restenosis. Baseline (Pre PTA) plasma samples were collected from healthy
controls and claudicants before PTA. Claudicants underwent arterial Duplex prior to and
4at 24 hours, one month, three month and six months following PTA to identify restenosis.
Plasma TF and TFPI levels were measured using standard enzyme linked immunosorbent
assay (ELISA).
Results: On reassessment of claudicants awaiting PTA, 30(64%) patients were stable whilst
10 (21%) and 7 (15%) had symptomatically improved or deteriorated respectively. 9
(19%) patients demonstrated disease progression on arterial duplex. As a result of
reassessment, 21 patients (45%) were removed from the PTA waiting list.
Plasma TF and TFPI concentrations were significantly higher in claudicants compared to
healthy controls. The baseline plasma TF and TFPI concentrations were significantly
higher in claudicants who developed restenosis following PTA than those who did not.
Following PTA, claudicants who developed restenosis showed higher concentrations of
plasma TF at 24 hour, 1 month, 3 month and 6 month follow-up intervals. Conversely,
the TFPI levels were significantly lower in the restenosis group at month 1 and 6
following PTA. The group differences did not reach statistical significance at day 1 and
month 3 following PTA. The ratio of baseline plasma TF and TFPI was found to be raised
significantly in claudicants who developed restenosis than those whose angioplasty site
remained patent.
Conclusions: 1.Claudicants awaiting PTA may experience a change in symptomatology
with time which might alter management decisions. In units with a long waiting list,
patients should be reassessed in the clinic to review symptom and evidence of disease
progression or regression.
2. Increased baseline plasma TF and TFPI levels are associated with restenosis following
PTA; however it is more likely that an altered TF/TFPI balance could be involved in the
occurrence of restenosis.
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Chapter 1 Introduction
1.1. PERIPHERAL ARTERIAL DISEASE (PAD) AND INTERMITTENT
CLAUDICATION (IC)
PAD is an important cause of morbidity and indicator of mortality for people in many
Western countries. About 20% of the UK population aged 55–75 years have evidence of
lower extremity peripheral arterial disease, of whom 5% presents with symptoms
(Norgren, Hiatt et al. 2007). In USA, the findings from a national cross-sectional survey
of PARTNERS (PAD Awareness, Risk, and Treatment: New Resources for Survival)
found that PAD affects 29% of patients aged ≥70 years or aged 50–69 years with a risk
factor for vascular disease (smoking, diabetes)(Hirsch and Hiatt 2001). The National
Health and Nutritional Examination Survey reported the prevalence of PAD 2.5% in the
age group 50–59 years to 14.5% in subjects >70 years on an unselected population of
2174 subjects aged ≥40 years (Selvin and Erlinger 2004). The clinical presentation of
PAD may vary from no symptoms to intermittent claudication, atypical leg pain, rest pain,
ischemic ulcers, or gangrene. Intermittent claudication (IC) is the commonest
manifestation of symptomatic PAD. It is a cramping pain in leg that develops when
walking and is relieved with rest. The prevalence of IC varies in different population
studies due to reporting bias. The Rotterdam study reported IC in 6.3% of patients with
PAD (Meijer, Hoes et al. 1998) In the Edinburgh artery study the prevalence of IC was
4.5% in 1592 patients with age group 55-74 years. The prevalence of IC increases with
age and in the relatively younger age group, claudication is more common in men but at
older ages there is little difference between men and women (Fowkes, Housley et al.
1991).
IC has 2 major consequences: The first is a decrease in overall well-being and quality of
life due to pain on walking and the second is a markedly increased cardiovascular
13
morbidity (myocardial infarction and stroke) and mortality.
Population follow-up studies suggest that symptoms in up to 50 % of patients with IC
remain stable or may even improve. Only approximately one quarter of patients with
intermittent claudication deteriorate progressively with an intervention rate of
approximately 5% (Jelnes, Gaardsting et al. 1986; Dormandy, Heeck et al. 1999).
Patients with IC have have a 2-4 % risk of undergoing non fatal cardiovascular event
within 1st year of diagnosis and a 1-3% yearly incidence thereafter (Norgren, Hiatt et al.
2007). In the Framingham Study, mortality in patients with IC was 2–3 times higher than
in age- and sex-matched control patients, with 75% of PAD patients dying from
cardiovascular events. The Edinburgh artery study reported increased cardiovascular
events and death in both asymptomatic PAD and IC (Fowkes, Housley et al. 1991).
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1.2. MANAGEMENT OF INTERMITTENT CLAUDICATION
The most important issue in the management of patients presenting with intermittent
claudication is the significant risk of developing cardiovascular complications; their
most serious problem is not the limitation of walking, although claudication may be the only
symptom. The clinical course of claudication is benign in most of the cases i.e. symptoms
usually remain stable or improve. Only approximately one quarter of patients with
intermittent claudication deteriorate progressively with an intervention rate of
approximately 5% (Jelnes, Gaardsting et al. 1986; Dormandy, Heeck et al. 1999)
The two primary goals in managing patients with IC are
1) Decrease cardiovascular morbidity and mortality by disease modifying therapy for
secondary prevention.
2) Improve limb related symptom and quality of life.
1.2.1. MODIFICATION OF RISK FACTORS
SMOKING CESSATION
Successful cessation of smoking in patients with IC is associated with decreased disease
progression, critical limb ischaemia, amputation rate, myocardial infarction, stroke and
increased long term survival (Quick and Cotton 1982; Jonason and Bergstrom 1987).
In smokers, advised to stop smoking along with a formal cessation program and nicotine
replacement therapy (NRT), a cessation rate of 22% have been observed at 5 years
(Norgren, Hiatt et al. 2007). Randomized studies have supported use of bupropion in
patients with cardiovascular disease (Tonstad, Farsang et al. 2003). Combining bupropion
and NRT has been shown to be more effective than either therapy alone (Jorenby,
Leischow et al. 1999). Varenicline a partial acetylcholine nicotinic receptor agonist has
been shown to be more effective than bupropion in achieving higher quit rate (Cahill,
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Stead et al. 2007).
LIPID LOWERING THERAPY
Low HDL (high density lipoprotein) or High LDL (low density lipoprotein): HDL ratio
are independent risk factor for PAD (Fowkes, Housley et al. 1991).
Evidence supporting the use of statins to lower LDL cholesterol levels in PAD comes
from the Heart Protection Study (Heart Protection Study Collaborative Group 2002).
20,536 subjects at high risk for cardiovascular events including 6748 patients with PAD
were randomized to simvastatin, antioxidant vitamins, a combination of treatments, or
placebo with a 5-year follow up. Use of simvastatin was associated with a 12% reduction
in total mortality, 17% reduction in vascular mortality, 24% reduction in coronary heart
disease events, 27% reduction in all strokes and a 16% reduction in non-coronary
revascularizations. A Cochrane review of studies in patients with PAD concluded that
lipid lowering therapy may be useful in preventing deterioration of underlying disease and
symptom alleviation (Leng, Price et al. 2000).
Trials have shown that use of statin was associated with increase in pain free walking
distance and quality of life (Mohler, Hiatt et al. 2003; Erez and Leitersdorf 2007).
A recent meta-analysis also showed that patients with PAD benefits from statin therapy
irrespective of baseline cholesterol concentration (Lewington, Whitlock et al. 2007).
DIABETES
Diabetes increases the risk of PAD approximately three to four-fold, and the risk of
claudication two-fold (Norgren, Hiatt et al. 2007). Edinburgh artery study and Health
Professionals Follow-up study showed 1.5-2.5 fold increase risk of symptomatic and
asymptomatic PAD in diabetics (Fowkes, Housley et al. 1991; Al-Delaimy, Merchant et
al. 2004). The UK prospective diabetes study (UKPDS) reported strong association of
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haemoglobin A1c (HbA1c) with risk of PDA (Adler, Stevens et al. 2002). The TASC
(TransAtlantic Inter-Society Consensus) guideline suggests that patients with diabetes and
PAD should have aggressive control of blood glucose levels with the aim of keeping
HbA1c of <7.0% or as close to 6% as possible (Norgren, Hiatt et al. 2007).
HYPERTENSION
Hypertension is a major cardiovascular risk factor present in up to 55% patients with PAD
(Lip and Makin 2003). Effective antihypertensive therapy can reduce progression of PAD
and mortality from myocardial infarction and stroke (Ostergren, Sleight et al. 2004;
Feringa, van Waning et al. 2006).
ANTIPLATELET THERAPY
Long-term use of antiplatelet agents reduces the rate of MI and ischaemic stroke in
patients with symptomatic PAD (Peripheral Arterial Disease Antiplatelet Consensus
Group 2003). The CAPRIE trial evaluated efficacy and safety of clopidrogel compared
with aspirin for secondary prevention in patients with cardiovascular disease; It showed a
reduction in the risk of MI, stroke and vascular death in favour of clopidrogel (CAPRIE
Steering Committee). The Peripheral Arterial Disease Antiplatelet Consensus Group
recommends long term use of either Aspirin 75-325 mg daily or Clopidogrel 75 mg per
day in all patients with intermittent claudication or who have had previous vascular
intervention (Peripheral Arterial Disease Antiplatelet Consensus Group 2003).
1.2.2. IMPROVEMENT OF LIMB RELATED SYMPTOM AND QUALITY OF
LIFE
EXERCISE PROGRAMME
Exercise training significantly improves walking capability in patients with intermittent
claudication. A meta-analysis performed by Gardner et al suggestesd the efficacy of
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exercise in improving the claudication related pain (Gardner and Poehlman 1995). A
systematic review of randomized controlled clinical trials by the Cochrane collaboration
group compared the effect of exercise programmes on IC with usual care or placebo
(Watson, Ellis et al. 2008). Exercise produced significant improvement in walking time
and walking distance. A systematic review of randomised controlled trials comparing
supervised vs unsupervised exercise programs for IC showed statistically significant
improvement in treadmill walking distance associated with Supervised exercise
programme (SEP) compared with non-supervised exercise therapy regimens
(Bendermacher, Willigendael et al. 2006). Supervised exercise programme (SEP) have
been recommended as first line treatment for treatment of claudication (Stewart, Hiatt et
al. 2002; Norgren, Hiatt et al. 2007).
PHARMACOLOGICAL THERAPY TO IMPROVE SYMPTOM OF IC.
Cilostazol is the drug with best evidence in support of its indication in treatment of IC. It
is a phosphodiesterase III inhibitor and is reported to have anteplatelet and vasodilator
effect. Two large systematic reviews have shown improvement in walking distance along
with improvement of quality of life (Regensteiner, Ware et al. 2002; Thompson, Zimet et
al. 2002). In these trials, the best benefits were observed in patients with short distance
claudication. Cilostazol is licensed in UK for symptomatic relief of IC.
Naftidrofuryl is reported to have vasodilator effect and is thought to improve tissue
oxygenation. Scottish Intercollegiate Guidelines Network suggests consideration to use
naftidrofuryl in patients with IC and a poor quality of life (Hainsworth 2006).
ENDOVASCULAR TREATMENT FOR CLAUDICATION
Interventional therapy is considered in a minority of patients with intermittent
claudication after balancing patient disability against procedural complication and
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likelihood of long-term success of the procedure (Dormandy 2000).
In general an intervention or revascularisation procedure is indicated in 1) significant
deterioration of symptom so as to severely handicap the patient in terms of preferred
daily activities and job. 2) Severe handicap of patient at presentation and 3)
development of critical ischaemia (Dormandy 2000).
The morphological categorization of femoropopliteal lesions may help to identify the
preferred therapeutic option. According to the Transatlantic Inter-Society Consensus
recommendation, PTA is the treatment of choice for TASC type A femoropopliteal
lesions (Table 1), and in selected patients with TASC type B and C lesions but more
evidence is required to make a firm recommendation about the preferred therapeutic
option (Dormandy 2000).
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Table 1. TASC grading for femoropopliteal disease*
TASC grade Lesion Characteristics
TASC A Single stenosis up to 3 cm; Not at superficial femoral artery origin or distal
popliteal artery.
TASC B  Single stenosis/occlusion 3-5 cm; not at distal popliteal artery.
 Heavy calcified stenosis up to 3 cm.
 Multiple lesions, each < 3 cm
 Single/ Multiple lesions in absence of continuous tibial runoff.
TASC C  Single stenosis/occlusion > 5 cm
 Multiple Single stenosis/occlusions each 3-5 cm with or without heavy
calcification.
TASC D Complete common femoral or superficial femoral artery occlusions or
complete popliteal and proximal trifurcation occlusions
* TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc
Surg, 2000.
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SUPERVISED EXERCISE VS ENDOVASCULAR TREATMENT FOR IC
Evidence is limited for exercise compared with angioplasty in treatment of intermittent
claudication due to small number of trials. Angioplasty is thought to produce greater
improvement in symptom in the short term but the effect may not be sustained (Watson,
Ellis et al. 2008). The randomized trial comparing exercise training vs. angioplasty at
Oxford showed greater rise in ABPI following angioplasty compared to exercise.
However exercise training confers greater improvement in claudication distance and
maximum walking distance (Perkins, Collin et al. 1996).
A randomized control trial of SEP, angioplasty and combined therapy in IC shows
greater benefit in clinical outcome in patients treated with both SEP and angioplasty
compared to patients treated by angioplasty or SEP (Mazari, Gulati et al.).
A prospective multicentre randomized controlled trial the CLEVER study is under way to
compare the clinical and cost effectiveness between SEP vs. endoluminal
revascularization in claudicants (Murphy, Hirsch et al. 2009).
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1.3. ENDOVASCULAR TREATMENT OF LOWER LIMB PAD IN HULL
As per mid year report 2009 from Office of National Statistics, Hull has a population of
262,400 with a population density of 3,673. Vascular disease is not uncommon in Hull,
partly attributable to prevalence of diabetes (4.5% in year 2006/2007 as per General
Practioners registers) and high prevalence of smoking. Hull’s Health and Lifestyle
Survey, 2007 by the Primary Care Trust reports an overall smoking prevalence of 32%,
which is way above the National prevalence of 22% in (2006).
In the year 2009 more than 300 cases of lower limb PTA was performed at Hull Royal
Infirmary. The therapeutic algorithm followed for treating patients with diagnosed
intermittent claudication is shown in figure 1. Table 2 and 3 shows the demographic
profile and the lower limb PTAs performed in 2009.
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Figure 1. Alogrithm for the Treatment of Intermittent Claudication
Author: P Kendrewand, Mr P Renwick, Hull and East Yorkshire Hospitals NHS
Trust. Approved March 2008.
Intermittent
Claudication
Secondary Prevention
Smoking cessation
Anteplatelets
Optimize
• Cholesterol lowering therapy
• Antihypertensive treatment
• Diabetic control
Symptomatic
Exercise (SEP recommended) Disabling symptom:
Imaging investigations with a view
to do PTA or Surgery
Non reconstructable via surgical
methods or unfit for surgery, initiate
Cilostazol
Cilostazol guidelines
• Only be initiated following recommendation by specialist team
• Should only be used in patients not amenable to surgery
• Should be given for 3 monthsthen effect reviewed by GP. Treatment should only
continue if benefit has been demonstrated
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Table 2. Demographic profile of patient who underwent PTA of lower limb vessels
at Hull Royal infirmary (Jan 2009- Dec 2009)
N= 316
Age= Median 70 (Iqr 62-77) years
M:F= 3.6:2
Percentage
Hypertension
Diabetes
Hypercholesterolemia
Renal failure
Current smoker
Ex smoker
Angina
MI
Symptomatic carotid disease
45.1
24.6
35
6
20.2
38.8
14.2
14.5
5.6
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Table 3. Endovascular treatment of lower limb vessels at Hull Royal infirmary (Jan
2009- Dec 2009)
PTA site Number
(percentage)
Bilateral Stent use
Iliac 105 (33.2) 45 (66.2) 48 (77.4)
Ileo femoral 41 (13) 14 (20.6) 7 (11.3)
Femoro popliteal 149 (47.2) 6 (8.8) 7 (11.3)
Ileo femoral with
distal vessels
15 (4.7) 3 (4.4) 0
Distal vessels only 6 (1.9) 0 0
Total 316 68 (100) 62 (100)
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1.4. Factors affecting outcome of femoropopliteal PTA
Despite increasing numbers of femoropopliteal PTA performed through out the world,
controversy still exists concerning outcomes, because often the reporting of indications and
results are not standardised. Varying reporting criteria may account for up to twofold
difference in reported five-year patency following femoropopliteal PTA (Matsi PJ, Manninen
HI 1995). Many studies group PTA for claudication and critical ischaemia together and
others fail to stratify the results (Harris RW et al 1991).
The factors that influence the outcome of PTA for lower extremity PAD include;
 Lesion characteristics
 Pattern of arterial disease
 Patient demographics
 Clinical presentation
 Intra procedural factors
1.4.1. Lesion Characteristics
1. Location
Long term patency following PTA is dependent on anatomical location of the lesion. Initial
and long-term results are best in proximal arteries with decreasing long-term patency for
more distal lesions. The early and late outcomes of femoropopliteal angioplasty are
inferior to that of iliac angioplasty. Twice the initial and early failure rate at one year has
been reported for PTA of femoropopliteal arteries than that of iliac arteries (Rutherford RB
1992). Similarly PTA of above knee popliteal lesions is associated with better results than
PTA of below-knee popliteal lesions (Johnston 1992).
2. Stenosis versus occlusion
In femoral and popliteal arteries higher rates of technical failures have been reported in
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occlusive lesions compared to stenosis (18% versus 7%)(Capek, McLean et al. 1991).
However the long-term patency rate in these two types of lesions may be similar. Some
series have shown better outcomes in stenosis rather than occlusion, whereas others have
found no difference (Rutherford 2000).
3. Length of the lesion
Length of the lesion directly affects the patency rates following PTA. Longer lesions
have a significant negative effect on the results of femoropopliteal PTA (Rutherford 2000).
Capek et al reported that lesion length correlates with outcome following PTA, with short
stenoses faring better with longer long term patency than long lesions (Capek, McLean et
al. 1991). The overall vessel patency rates after femoropopliteal PTA in this study were
81%, 61%, and 58% at one, three, and five years.
4. Multiple stenoses in same segment
Lesions with multiple stenoses are associated with more frequent residual stenosis
following PTA and higher restenosis rates. The outcome following femoropopliteal PTA
involving multiple stenosis are inferior to those following PTA of focal stenosis (Johnston
1992).
5. Other Morphologic features
Calcification of stenotic lesions may affect outcome following PTA. Heavily calcified
lesions are more prone to rupture, dissection and residual stenosis following PTA
(Rutherford 2000). Eccentricity of the lesion has been considered to correlate with poor
outcome following PTA in some studies, however this may not be an important factor for
long term patency following PTA provided good haemodynamic correction
has been achieved. In femoropopliteal PTA lesion eccentricity is associated with higher
rates of early failure due to dissection (Capek, McLean et al. 1991).
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1.4.2. Pattern of arterial disease
The pattern of disease indicates the extent of atherosclerotic involvement and the runoff
status, which might influence the success rate of PTA.
1. Multilevel Occlusive disease
PTA may be indicated to treat stenosis or occlusion at more than one arterial segment.
Each site has its own failure rate and failure at one site may negatively affect the outcome
at other sites.
2. Runoff status
Runoff status has been found to be a significant prognostic factor in the outcome
following endovascular intervention (Capek, McLean et al. 1991; Johnston 1992).
Studies on femoropopliteal PTA have shown that outcome is influenced by the runoff
status. Krepel et al (1985) reported a five-year success rate of 77% and 59% for patients
with good runoff and poor runoff, respectively. Gallino and associates have reported better
early and late success rates following femoropopliteal PTA in patients with two or three
patent tibial arteries than in patients with one or no tibial arteries (Gallino, Mahler et al.
1984). Stanley et al reported a 55% 2-year patency rate in limbs with good runoff and 23%
in limbs with poor runoff following femoropopliteal PTA (Stanley, Teague et al. 1996).
1.4.3. Patient demographics
1. Gender
Women tend to have a lower patency rate following PTA than men (Mehilli, Kastrati et
al. 2003).
2. Diabetes
Presence of diabetes correlates poorly with outcome (Gallino, Mahler et al. 1984; Jeans, Cole
et al. 1994). However this may be due to the pattern / distribution of atherosclerotic
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lesions in the diabetic population, which have a predominance in the
infrapopliteal vessels. For the same combination of occlusive lesions, no significant
difference between diabetes and non-diabetics was observed (Davies, Cole et al. 1992).
Diabetic patients with good runoff fare better than those with poor runoff after
femoropopliteal PTA (Stokes, Strunk et al. 1990)
3. End stage renal disease
Increased incidence of restenosis has been reported in patients with end stage renal disease
following coronary angioplasty (Schoebel, Gradaus et al. 1997). This is considered to be
due increased prothrombotic risk associated with higher fibrinogen concentrations in
these patients (Rabelink, Zwaginga et al. 1994; Schoebel, Gradaus et al. 1997).
1.4.4. Clinical presentation
Indication for intervention is one of the strongest predictors of outcome following
femoropopliteal PTA. Successful long-term outcome following femoropopliteal PTA is
less likely with more advanced lower limb ischaemia. Patients with claudication tend to have
a more benign overall disease than those with critical ischaemia. Claudicants have better
long-term success rates than patients with critical limb ischaemia (Johnston 1992). Hunick
and associates reported better five-year patency rates in claudicants than those who had
critical ischaemia (55% vs. 29%) following PTA for stenotic lesions (Hunink, Donaldson
et al. 1993).
1.4.5. Intra-procedural factors
Events occurring during the angioplasty might influence early and long term outcome.
Intra-procedural complications like dissection, significant residual stenosis and poor
haemodynamic result may influence long term outcome following PTA (Rutherford 2000).
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1.5. MECHANISM OF PTA
Dr. C. Dotter performed the first endovascular procedure by dilating an iliac artery stenosis
with the sequential passage of progressively larger catheters across the lesion (Dotter CT,
Judkins MP 1964). Andreas Gruntzig introduced the concept of the double lumen catheter
and increased the application of percutaneous catheter based vascular dilatation (Gruntzig
AR 1979). Balloon catheters allowed vascular dilatation through sites remote from the
target lesion. In the past decades, the development of flexible guide wires, has facilitated
access for the dilatation of lesions in distant smaller tortuous arteries. Percutaneous
transluminal angioplasty is an increasingly common endovascular procedure performed in
the aorta, iliac, femoral, tibial and coronary arteries with varying degrees of success.
Balloon angioplasty expands a narrowed arterial segment in a manner that retains the
expansion thereby improving blood flow through the dilated arterial segment. Balloon
angioplasty functions by exerting a circumferential force on the arterial wall as the balloon
expands. The pressure generated by fluid forced in to the contained space of the balloon
during dilatation results in the generation of a circumferential stretching force on the
arterial wall. This circumferential stretching force acting on the balloon surface is called
‘Hoop stress’ and may be calculated using the equation,
Hoop stress = hydrostatic pressure X balloon diameter (Abele 1980).
Hoop stress generates both longitudinal and radial force vectors with the radial component
being the dilating force. The radial force is directly proportional to the diameter of the
fully inflated balloon and the pressure used for balloon inflation (Castaneda-Zuniga,
Formanek et al. 1980). The radial force is thus greater than the hydrostatic force of fluid
injected in the balloon. During angioplasty the increase in intraluminal pressure and radius
results in an increased tangential force, which keeps the arterial wall expanded. The force
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generated by the balloon in a stenotic area varies with radial force vectors being greatest
at the area of greatest stenosis (Abele 1980; Castaneda-Zuniga, Formanek et al. 1980).
The hoop stress also acts on the adjacent normal compliant artery thus causing elastic
stretching of the compliant adjacent artery. Angioplasty balloons are made of non-compliant
material thus retain their diameter with increasing pressure. This prevents excessive
overstretching of the adjacent normal arterial segment during balloon dilatation.
Current knowledge regarding the mechanism of luminal gain following PTA is based on
animal models, autopsy and atherectomy specimens, and intravascular ultrasound
studies. Balloon dilatation of the inelastic stenotic lesions causes significant intimal trauma
(Castaneda-Zuniga, Formanek et al. 1980; Lyon, Zarins et al. 1987). When a fibrocalcific
plaque is dilated during PTA, the radial force vectors separate the inelastic plaque from
adjacent compliant artery. The shearing force at the interface separates the plaque and the
compliant arterial wall (usually tunica media). This separation creates a dissection that is
rapidly extended radially by the pressure exerted by the balloon. This dissection is necessary
for the irreversible expansion of the arterial lumen (Neville RF 1997). The resultant healing
process and arterial remodelling obliterates the dissection planes, rendering it
angiographically invisible within 3 to 30 days post PTA (Lyon, Zarins et al. 1987).
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1.6. RESTENOSIS FOLLOWING ANGIOPLASTY
Restenosis may be defined as the recurrence of impaired lumen area after successful
angioplasty. This has been characterized conventionally by quantitative angiography and
most commonly confirmed by a diameter reduction of 50% or more at follow-up
following a successful angioplasty.
1.7. METHODS OF DETERMINATION OF RESTENOSIS
Restenosis following endovascular intervention can be identified by conventional
angiography, duplex sonography, intravascular ultrasound, angio-computed tomography
and magnetic resonance imaging. Despite all these techniques, restenosis is often diagnosed
by symptom recurrence and resulting end organ dysfunction.
1.7.1. Contrast angiography
Angiography is considered the gold standard for defining both normal vascular anatomy and
pathology. It remains the only universally accepted imaging modality to guide percutaneous
intervention. Over the decades although many definitions of angiographic restenosis have
been used, the most widely used and accepted is recurrent stenosis greater than 50%
(Miller J M 1999). Arterial remodelling offers particular challenges to angiographic
interpretations because angiography only visualizes the contrast filled vessel lumen (Topol
and Nissen 1995). Up to 40 % of the internal elastic lamina may be occupied before the
lumen begins to narrow (Glagov, Weisenberg et al. 1987). Angiography is considered to
be an end point in defining clinical restenosis however discrepancies between
angiographic and clinical outcomes are not unusual (Miller J M 1999).
1.7.2. Duplex ultrasound
Duplex ultrasound is useful to detect stenosis and determine its anatomical location in
lower extremity PAD. The most commonly used quantitative criteria to detect stenosis is
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the ratio of the peak systolic velocity within the stenosis and the adjacent normal
arterial segment. A ratio of greater than 2 is commonly used to diagnose a stenosis which
reduces the luminal area of the artery by greater than 50% (Fletcher, Kershaw et al. 1990;
Moneta, Yeager et al. 1993; Pinto, Lencioni et al. 1996). There is conflicting evidence
regarding the value of duplex ultrasound in surveillance following angioplasty. Studies
suggest that immediately after angioplasty, velocities in the treated segment are abnormally
elevated and do not predict subsequent patency rates (Sacks, Robinson et al. 1990; Sacks,
Robinson et al. 1994). Ultrasound however is valuable in the evaluation of chronic recurrent
stenoses (Spijkerboer, Nass et al. 1996; Vroegindeweij, Tielbeek et al. 1997).
1.7.3. Magnetic resonance imaging (MRA)
Similar to duplex imaging, MRA can be used to delineate anatomical location and degree
of stenosis in patients with PAD. MRA has also been used in assessment of post
endovascular intervention of the lower extremities. MRA in post procedure evaluation of
angioplasty sites demonstrates concordance with catheter angiography in 80-95% cases
(Davis, Schopke et al. 1997).
1.7.4. Intravascular Ultrasonography
The use of intravascular ultrasound has broadened our understanding of plaque
morphology and arterial remodelling following percutaneous intervention. As it can
measure both external and internal vessel diameter, it has been used to confirm Glagov
phenomenon (Glagov, Weisenberg et al. 1987) which describes that arteries remodel to
maintain constant blood flow despite increase in atherosclerotic lesion mass. Mintz et al
demonstrated negative arterial remodelling by performing serial intravascular
ultrasound studies of angioplastied vessels in human coronary arteries (Mintz, Popma et al.
1996).
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1.8. CURRENT CONCEPT IN MECHANISM OF RESTENOSIS
The development of a restenotic lesion differs from the development of a primary
atherosclerotic lesion in many ways. Primary atherosclerotic lesion develops over years,
whilst restenosis most commonly occurs within the first 6 months following intervention
(Nobuyoshi, Kimura et al. 1988; Serruys, Luijten et al. 1988). The pathophysiology of
restenosis is complex and incompletely understood. Current evidence suggests that
restenosis is an abnormal response of the artery to angioplasty trauma and consists of
thrombosis, inflammation, cellular proliferation, and extra cellular matrix production
(Nikol, Huehns et al. 1996). The lumen loss after angioplasty may be divided in to 3
distinct stages: early luminal loss associated with elastic recoil, late loss secondary to
negative vascular remodelling and neointimal hyperplasia (Rajagopal and Rockson
2003).
1.8.1. Elastic recoil
Elastic recoil is a progressive phenomenon that occurs immediately following
angioplasty resulting in immediate luminal loss. By using quantitative coronary
angiography in 154 angina patients undergoing PTCA, Caixeta and colleague observed a
34% loss in lumen diameter within 15 minutes of balloon deflation (Caixeta, Arie et al.
1996). Studies indicate that elastic recoil may account for up to 50% of the loss in lumen
gain during angioplasty (Rozenman, Gilon et al. 1993; Rodriguez, Palacios et al. 1995).
The degree of elastic recoil following angioplasty varies in different arteries due to
variation in elastin content. Most studies of arterial wall recoil are focussed on coronary
arteries (Rensing, Hermans et al. 1990; Kimball, Bui et al. 1992; Caixeta, Arie et al. 1996;
Bermejo, Botas et al. 1998). Pasterkamp et al reported 11% elastic recoil in femoral arteries
following angioplasty, using intravascular ultrasound (Pasterkamp, Borst et al. 1995).
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Gardiner et al reported 32% elastic recoil in a study involving balloon angioplasty for iliac
artery stenosis and showed the influence of balloon artery ratio on the degree of elastic
recoil (Gardiner, Bonn et al. 2001). Elastic recoil following angioplasty may be reduced by
stent implantation. However even after stenting, luminal diameter is usually <60% of the
maximum achievable diameter due to suboptimal stent deployment and elastic recoil
(Bermejo, Botas et al. 1998).
1.8.2. Vascular Remodelling
Vascular remodelling occurs naturally in atherosclerosis. Glagov et al noted
compensatory enlargement of human coronary arteries in response to plaque formation to
reduce the effect of arterial lumen narrowing (Glagov, Weisenberg et al. 1987). In vivo
confirmation of this positive remodelling was reported by Losordo et al (Losordo, Rosenfield
et al.1994). Studies involving animal and human subjects have established an alternate form
of arterial remodelling, the constrictive or negative remodelling. Following angioplasty
constrictive remodelling results in narrowing of vessel diameter causing restenosis of the
angioplastied segment. Mintz et al, using serial intravascular ultrasound, documented
negative remodelling resulting in restenosis following human percutaneous transluminal
coronary angioplasties (PTCA) (Mintz, Popma et al. 1996). They observed that the change
in lumen area between post PTCA and late angiographic follow-up correlated strongly to a
change in vessel size (area circumscribed by the external elastic lamina) rather than the
change in area of atherosclerotic plaque plus medial wall of the artery. The study showed that
the change in vessel size is bi-directional. Some lesions showed an increase in vessel size
where as others showed a decrease in vessel size. Lesions that exhibited an increase in
vessel size had no change in lumen area in contrast to the lesions that exhibited a decrease in
vessel size associated with reduction of lumen area. Figure 2 shows a simplied diagram of
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positive and vascular remodeling in response to atherosclerotic plaque formation. The
precise mechanism of arterial remodelling after angioplasty is uncertain but is likely to be
multifactorial and include a combination of elastic recoil, disordered flow mediated
remodelling, adventitial scar contraction and thinning of tunica media (Isner 1994). Current
data suggest vascular remodelling may be due to adventitial thickening and scar contraction
as a result of replacement of hyaluronic acid with collagen in the extra cellular matrix
(Riessen, Wight et al. 1996). The extent, negative remodelling plays in restenosis is debated,
but is thought to be more predominant following simple angioplasty whereas neointimal
hyperplasia is thought to predominate in restenosis following angioplasty and stenting
(Bauters and Isner 1997).
Figure 2. Positive and negative arterial remodelling in response to atherosclerotic
plaque formation
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maintain the blood
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Negative remodelling
types of remodeling in a blood vessel in response to atherosclerotic
ositive remodeling is an adaptative expansion of the arterial wall to
flow through blood vessels in response to atherosclerotic plaque
remodeling there is a failure of the arterial wall to expand or an
sulting in reduction in luminal area (Glagov, Weisenberg et al. 1987).
Positive remodelling
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1.8.3. Neointimal Hyperplasia
Intimal hyperplasia is an exuberant response to healing in blood vessels following an open
or endovascular procedure that can compromise vessel lumen, restrict blood flow and may
ultimately result in failure of the interventional procedure. Intimal hyperplasia occurs within
months of intervention and is a complex cellular process predominantly involving the
intimal layer of the artery. It may be triggered by a combination of trauma causing endothelial
injury coupled with turbulent blood flow. Immediately following angioplasty, fracture of
atherosclerotic plaque exposes its thrombogenic contents triggering platelet adhesion,
activation and thrombosis (Fuster et al. 1990; Casscells, Engler et al. 1994).
Endothelial denudation results in the loss of antithrombotic factors (nitric oxide,
prostacyclin, tissue plasminogen activators), further contributing to platelet adhesion and
aggregation. Activated platelets release mitogens including thromboxane A2, serotonin,
platelet derived growth factor which promote smooth muscle cell proliferation and
migration(Bauters and Isner 1997; Dorn 1997; Pakala, Willerson et al. 1997). Concurrently
the levels of mitogenic protooncogenes (c-fos, c-jun, fosB, junB and junD) increase in
the smooth muscle cells, altering their phenotype from contractile to synthetic type
(Miano, Vlasic et al. 1993). In contrast to the vasoactive, contractile (differentiated)
smooth muscle cells, the synthetic type (undifferentiated) are highly proliferative
(Chamley, Campbell et al. 1977). Additionally smooth muscle cells secrete promigratory
proteins including CD44v6, urokinase plasminogen activator receptor, integrin alpha(v)ss,
transforming growth factor ss, MDC9 and ss-inducible gene h3 (Bauters and Isner 1997;
Rajagopal and Rockson 2003). Consequently, many activated medial smooth muscle cells
migrate to the intima (Miano, Vlasic et al. 1993). An injured, dysfunctional endothelium
may also contribute to smooth muscle proliferation and migration as an intact endothelium
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may exert antiproliferative influence on the underlying smooth muscle cells possibly
mediated by prostacyclin and nitric oxide, heparin sulphate and nitric oxide (Clowes,
Clowes et al. 1986; Bauters and Isner 1997). The proliferative response of the smooth
muscle cells peaks 4 weeks after initial injury before slowing down until the number of
intimal smooth muscle cells stabilizes 6 months post injury. At this point much of the
hyperplastic response is contributed by increase in extra cellular matrix from secretory
activity of synthetic smooth muscle cells and fibroblasts. The mature intimal lesion is 60%-
80% extra cellular matrix by volume (Neville and Sidawy 1998). The extra cellular
matrix continues to increase despite reestablishment of endothelial layer. One year post
injury lesions exhibit decreased smooth muscle cellularity with a persistent increase in extra
cellular matrix (Fuster et al. 1990; Clowes and Reidy 1991).
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1.9. MOLECULES INVOLVED IN INTIMAL HYPERPLASIA
1.9.1. Mitogen activated protein kinases (MAPKs)
MAPKs are a family of serine threonine protein kinases activated by a range of stimuli
including growth factors, cytokines, shear stress, vasoactive agents, and oxidative stress
(Khan, Bianchi et al. 2004). The MAPK family members are involved in intracellular
signalling cascades that transduce extra cellular stimuli into a cellular response by
activating cytoplasmic and nuclear effector proteins, ultimately modifying gene
transcription. The three major members of MAPK family, implicated in vascular
response to injury are: a) extra cellular signal regulated kinases (ERKs); b) p38 MAPK ,
and c) c-Jun N-terminal kinases (JNKs) (Koyama, Olson et al. 1998; Tanaka, Oda et al.
1998; Yu, Ferrari et al. 2007). Activation of certain members of MAPKs regulates
inflammatory response to vascular injury. p38 MAPK activation is involved in
production of proinflammatory cytokines (IL-1β, TNF- α) and activation of monocytes,
macrophages and T- lymphocytes (Lee, Laydon et al. 1994). JNK up regulates
expression of proinflammatory genes encoding for cell surface receptors, cell adhesion
molecules, growth factors and cytokines (Manning and Davis 2003). MAPKs also mediate
endothelial and vascular smooth muscle cells (VSMC) proliferation and migration induced
by growth factors involved in development of intimal hyperplasia (Yu, Ferrari et al. 2007).
1.9.2. Thrombin
Thrombin is a serine protease which, in addition to its well recognised enzymatic role in the
coagulation cascade, serves as an effector molecule to elicit cellular responses. Thrombin
affects different cell types through activation of protease activated receptors (PARS) which
translates extra cellular proteolytic events in to intracellular signalling (Coughlin 2005).
Thrombin is a strong mediator of inflammation, a process intimately linked to
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development of intimal hyperplasia (Cirino, Cicala et al. 1996; Erlich, Boyle et al. 2000;
Fukuda, Shimada et al. 2004). Thrombin promotes leukocyte migration, stimulates secretion
of growth factors and platelet activating factor (Strukova 2001; Minami, Sugiyama et al.
2004). Migration and proliferation of vascular smooth muscle cells in response to injury
are also stimulated by thrombin (Li, Garnette et al. 2000; Cao, Dronadula et al. 2006).
1.9.3. Platelet derived growth factors (PDGFs)
PDGFs are peptide growth factors that are released predominantly by activated platelets at
the site of vascular injury and by stress stimulated endothelial cells (Dardik,
Yamashita et al. 2005). PDGFs play important role in neointimal hyperplasia. One
isoform of PDGF (PDGF-BB) is a very potent stimulator of VSMC migration. Another
isoform, PDGF-AA stimulates VSMC proliferation but not migration (Koyama, Hart et al.
1994; Uchida, Sasahara et al. 1996). In vitro studies have shown that the effect of PDGFs
on VSMC are mediated by MAPKs (Kingsley, Huff et al. 2002; Zhan, Kim et al. 2003).
1.9.4. Fibroblast growth factor-2 (FGF-2)
FGF-2 is a pleiotropic growth factor and controls a variety of physiological and
pathological functions including angiogenesis and neointimal hyperplasia (Bikfalvi, Klein
et al. 1997; Ornitz and Itoh 2001). Tissue damage including vascular injury induces
both the release and expression of FGF-2 (Pintucci, Steinberg et al. 1999; Rhoads, Eskin
et al. 2000) and FGF-2 then induces VSMC proliferation and migration (Rauch, Millette et
al. 2005). FGF-2 mediated activation of MAPKs is implicated in reendothelialization and
VSMC proliferation and migration following vascular injury (Pintucci, Steinberg et al.
1999).
1.9.5.Transforming growth factor- f3 (TGF-f3)
TGF-f3 is a pleiotropic cytokine produced by platelets, vascular endothelial cells, VSMCs,
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and inflammatory cells. It is a key regulator of cell migration, proliferation, differentiation
and apoptosis (Roberts 1998; Schulick, Taylor et al. 1998). Induction of TGF-f3 has been
implicated in the regulation of the cellular response to vascular injury. Haemodynamic shear
forces secondary to vascular injury induce release of TGF-f3 from endothelial cells (Song,
Kocharyan et al. 2000). It is uncertain whether TGF-f3 is a positive or negative regulator
of intimal hyperplasia. TGF-f3 increases ECM deposition and some studies suggest that it
promotes intimal hyperplasia (Schulick, Taylor et al. 1998). More recently it has been
suggested that TGF-f3 could inhibit VSMC proliferation and migration (Seay, Sedding
et al. 2005).
1.9.6. Matrix metalloproteinases (MMPs)
Matrix metalloproteinases (MMPs) are extra cellular matrix (ECM)-modifying enzymes
that play a significant role in pathogenesis of restenosis by regulating ECM degradation and
release of matrix degrading MMPs. Two types MMPs have been particularly implicated in
restenosis namely MMP-2, and MMP-9 (Dollery, McEwan et al. 1995; Loftus and
Thompson 2002). Remodelling of ECM after vascular injury facilitates migration and
proliferation of VSMCs, and MMPs play an essential role in this (Galis and Khatri
2002). Induction of MMP is considered important in the development of intimal
hyperplasia. Inflammatory mediators that play a role in the development of intimal
hyperplasia are involved in the control of MMPs activity (Yu, Ferrari et al. 2007).
MMPs play important role in constrictive arterial remodelling following vascular injury.
Constrictive remodelling in response to angioplasty is believed to be the result of
changes in collagen and elastin metabolism mediated by alterations in MMP activity after
angioplasty (Post, Borst et al. 1995). Several studies demonstrate a reduction in post
angioplasty constrictive remodelling and neointimal hyperplasia after administration of
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MMP inhibitors (de Smet, de Kleijn et al. 2000; Peterson, Porter et al. 2000; Sierevogel,
Pasterkamp et al. 2001).
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1.10. TISSUE FACTOR
Tissue factor, formerly known as thromboplastin is a 47-kDa cell bound transmembrane
glycoprotein expressed in both vascular and nonvascular cells. TF has been considered an
important initiator of coagulation in vivo since its discovery in the 19th century (Rapaport
and Rao 1995). Traditionally TF is believed to be the initiator of the extrinsic pathway of
coagulation. However with the increase in understanding of the role of TF and its
regulator, the tissue factor pathway inhibitor (TFPI), TF has also been shown to be a
cellular signalling receptor (Petersen, Freskgard et al. 2000) and has several non-
haemostatic actions. The pathways by which TF initiates cellular mechanisms are not clear.
It has been suggested that TF may influence coagulation dependent mechanisms involving
coagulation proteases (Abe, Shoji et al. 1999; Camerer, Rottingen et al. 1999; Ollivier,
Chabbat et al. 2000; Petersen, Freskgard et al. 2000) and coagulation independent
mechanisms involving its cytoplasmic domain (Abe, Shoji et al. 1999; Ruf and Mueller
1999).
44
1.11. TISSUE FACTOR AND COAGULATION
Tissue factor, a class 2 cytokine receptor, is a transmembrane glycoprotein that consists of
three sections: a large extra cellular domain, a transmembrane domain and a cytoplasmic
tail (Edgington, Mackman et al. 1991; Martin, Boys et al. 1995). The extra cellular domain
is important for haemostatic activity (McVey 1999). The transmembrane portion is
necessary for stabilization of the molecule and its complex. The function of the
cytoplasmic domain, although not yet fully determined, is considered to be involved in
the coagulation independent functions of TF (Abe, Shoji et al. 1999; Ruf and Mueller
1999). Traditionally TF was thought to initiate the extrinsic coagulation pathway, with
collagen playing the same role in the intrinsic pathway. The biochemical events of
coagulation are organised into the extrinsic, intrinsic and common pathways in the
cascade mechanism of coagulation (Fig. 3) (Davie and Ratnoff 1964; Macfarlane 1964).
The extrinsic pathway is initiated by TF interacting with factor VII to form activated factor
VII, which in turn activates factor X to form activated factor X (Xa). The intrinsic pathway is
initiated when factor XII comes in contact with negative charges underlying
endothelium and also generates factor Xa. Factor Xa catalyses conversion of prothrombin
to thrombin which combines with factor XIII to generate a fibrin plug. Several clinical and
experiential observations suggest that the cascade/ waterfall hypothesis does not accurately
reflect the events of in vivo haemostasis (Biggs and Mac 1951; Macfarlane, Biggs et al.
1964; Ragni, Lewis et al. 1981). Ostend and Rapaport provided experimental evidence that
factor VIIa-TF complex activates both factor X and IX indicating a central role of TF in
initiation of coagulation (Osterud and Rapaport 1977). The discovery of circulatory
inhibitor of factor VIIa-TF complex suggested an alternative ‘network’ model of
coagulation, which involves linkage of two pathways and is regulated by positive and
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negative feedback loops (Broze 1992; Rapaport and Rao 1992; McVey 1999). The
modern concept of coagulation incorporates cell surfaces in the coagulation process and
TF has a central role in this new concept of coagulation (Fig 4). The process of clot
formation is considered to occur in two stages: a) initiation of coagulation and b)
propagation of the resultant thrombus. The initiation phase begins when disruption of the
vessel wall exposes TF to circulating factor VII, forming a proteolytic active TF/
factor VIIa complex (TF-FVIIa) (Higashi and Iwanaga 1998). TF-FVIIa complex
activates factor IX as well as factor X on the sub endothelial surface (Bauer, Kass et al.
1990; Butenas, van 't Veer et al. 1997). The amount of FXa generated during this phase is
extremely low for formation of a fibrin plug. Trace amount of thrombin are generated
which initiates back-activation of factors V, VIII and possibly XI. Factor VIIIa then
complexes with IXa to generate a sufficient amount of Factor Xa that will sustain clot
formation (propagation phase). Traditionally it was believed that TF was only
expressed in extra vascular tissues by macrophages, monocytes, and fibroblasts
(Wilcox, Smith et al. 1989; Fleck, Rao et al. 1990). However TF is also found in the
adventitia of blood vessels, organ capsules, and epithelium of skin and mucous
membranes. TF is unable to interact with coagulation factors, and thereby initiates
thrombosis at these sites when vessel wall damage occurs. Circulating TF is present in both
the whole blood and serum of healthy individuals (Giesen, Rauch et al. 1999; Giesen and
Nemerson 2000). Normally, circulating TF is present at extremely low levels, and is
present in an inactive encrypted form, and therefore does not initiate coagulation. TF
inactivity may be caused by asymmetrical distribution of negatively charged phospholipids
across the cell membrane (Bevers, Comfurius et al. 1998). The phospholipids, required for
binding of coagulation factors to cell membrane and TF-VIIa complex, may be presented
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by cell membrane disruption. In the revised hypothesis of coagulation, TF rather than
the contact factors is responsible for initiation of coagulation. Factor IX and factor VII
are necessary for enhanced factor Xa generation and sustained coagulation.
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Figure 3. Cascade/ waterfall theories of coagulation
Figure showing cascade model of coagulation in which the biochemical events of
coagulation are organised into the extrinsic, intrinsic and common pathways. The
extrinsic pathway is initiated by TF interacting with factor VII to form activated factor VII,
which in turn activates factor X to form activated factor X (Xa). The intrinsic pathway is
initiated when factor XII comes in contact with negative charges underlying
endothelium and also generates factor Xa. Factor Xa catalyses conversion of prothrombin
to thrombin which combines with factor XIII to generate a fibrin plug.
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Figure 4. Revised theory of coagulation
In the revised model, the clot formation occurs in two stages: a) initiation of coagulation
and b) propagation of the resultant thrombus. The initiation phase begins when injury to
the vessel wall exposes TF to circulating factor VII, forming TF-VIIa complex. TF-
FVIIa complex activates factor IX as well as factor X on the sub endothelial surface. The
thrombin generated in the process initiates back-activation of coagulation factors V,
VIII and possibly XI. Factor VIIIa then complexes with IXa to generate a sufficient
amount of Factor Xa that will sustain clot formation (propagation phase).
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1.12. TISSUE FACTOR IN INTRACELLULAR SIGNALING
The structural similarities between TF and the super family of cytokine receptors,
especially interferon α, β and γ receptors were identified in 1990 (Bazan 1990). However it
took sometime before TF induced intracellular signalling was identified. Intracellular
signalling by TF-FVIIa complex mediates the non-haemostatic functions of tissue factor
including induction of proinflammatory response, migration and proliferation of
VSMC, tumour angiogenesis and metastasis. Binding of FVIIa to membrane bound TF
causes several intracellular effects (Petersen, Freskgard et al. 2000; Monroe and Key
2007) including: a) mobilization of intracellular calcium stores (Rottingen, Enden et al.
1995) b) transient phosphorylation of intracellular proteins like MAPKs (Poulsen, Jacobsen
et al. 1998; Versteeg, Bresser et al. 2003). Phophorylated MAPKs enter the cell nucleus
and activate several transcription factors. MAPKs activity are implicated in tumour
metastasis, VSMC proliferation and migration. Although the precise pathway of
intracellular signalling by TF-FVIIa and target cell effect is not clear, it is likely that
TF-FVIIa signals through activation of members of the family of protease activated
receptors (PARS) (Camerer, Huang et al. 2000; Riewald and Ruf 2002).
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1.13. TISSUE FACTOR PATHWAY INHIBITOR (TFPI) AND REGULATION OF
COAGULATION
TFPI is a multivalent, kunitz type, protease inhibitor which produces FXa dependent
feedback inhibition of TF- FVIIa complex (Broze 2003). The TFPI has a N-terminal
acidic region, three kunitz type domains (stable peptide domains with ability to recognize
specific protein structures and also act as competitive protease inhibitors) separated by two
linker regions, and a C-terminal basic region. K1 inhibits factor VIIa complexed to TF. K2
inhibits factor Xa (FXa). No direct protease inhibiting action has been demonstrated for
K3. The C terminal basic region is demonstrated to be required for rapid inhibition of
coagulation and for inhibition of smooth muscle proliferation (Bajaj, Birktoft et al. 2001).
The heparin binding sites of TFPI are located in the K3 domain and the C terminal
basic region of the molecule (Kato 2002).
The anticoagulant action of TFPI is a two stage process (Fig. 4). At first the TFPI binds to
FXa to form TFPI-FXa complex. The TFPI-FXa complex then binds to TF-FVIIa
forming a quaternary complex which completely blocks TF-VIIa activity and prevents
further activation of factor X (Price GC 2004). This process does not occur in the absence
of FXa indicating coagulation must be initiated before TFPI can function. There
are three pools of TFPI distribution in vivo. The first pool of TFPI is the largest (80-85%)
and is bound to vascular endothelium. The second pool (10%) circulates in plasma,
primarily in association with lipoproteins but a small amount is in a free form. The third
TFPI pool is the smallest (approximately 3%) and is found within platelets (Broze, Lange et
al. 1994; Bajaj, Birktoft et al. 2001). In the second pool, the lipoprotein associated TFPI is
C-terminally truncated and thus exhibits less anticoagulant activity. The free plasma
TFPI is full length but its concentration is insufficient to influence coagulation (Broze,
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Lange et al. 1994; Broze 1995). In the first pool TFPI is constitutively expressed on the
endothelial cell surface and is stored intracellularly (Kato 2002). Thrombin induces release
of TFPI from the intracellular stores and alters the cell surface distribution (Lupu, Lupu et
al. 1995). The synthesis and secretion of TFPI is also increased by heparin thereby
decreasing the procoagulant activity of the cells. Serum growth factors and shear stress also
up regulate TF expression (Hansen, Svensson et al. 2000; Kato 2002).
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1.14. TF AND TFPI IN CARDIOVASCULAR DISEASE
Hypertension
Tissue factor antigen in plasma is elevated in hypertensive subjects compared to
normotensive controls and can be lowered by antihypertensive drugs (Felmeden,
Spencer et al. 2003). Angiotensin II has been shown to induce TF expression in
monocytes, endothelial cells and VSMCs through angiotensin type I receptor (AT-I)
(Taubman, Marmur et al. 1993; He, He et al. 2006). Both ACE inhibitors and AT-I receptor
blockers reduce plasma TF activity in hypertensive patients (Koh, Chung et al. 2004).
Hyperglycaemia
In vitro studies suggest that hyperglycaemia induces thrombin induced TF expression of
endothelial cells (Boeri, Almus et al. 1989). In healthy humans, glucose intake also up
regulates monocyte TF expression. Increased plasma levels of TF are observed in
patients with diabetes mellitus and TF levels are reduced by improving glycaemic
control (Sambola, Osende et al. 2003). It has also been suggested that increased TF
level is associated with micro vascular and neurogenic complications in patients with Type
2 diabetes and is possibly a marker for micro vascular disease progression (Sommeijer,
Hansen et al. 2006). Alterations in TFPI activity in diabetics have been considered to reflect
early endothelial dysfunction (Leurs, van Oerle et al. 1997). Increased TFPI levels have been
reported in patients with diabetes mellitus, particularly in those with nephropathy associated
with insulin dependent diabetes (Yokoyama, Myrup et al. 1996; Leurs, van Oerle et al.
1997).
Hyperlipidaemia
Oxidised LDL increases TF expression in endothelial cells, monocytes and
macrophages (Drake, Hannani et al. 1991; Wada, Kaneko et al. 1994) where as HDL
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has been shown to inhibit endothelial TF expression (Viswambharan, Ming et al. 2004).
Patients with elevated LDL levels show increased plasma TF activity (Sambola, Osende et
al. 2003). Statins reduce TF expression in monocytes, endothelial cells, and VSMCs (Eto,
Kozai et al. 2002). Based on animal studies, it has been suggested that the reduction in
TF expression is, at least in part, related to pleiotropic anti inflammatory effect of these
drugs (Bea, Blessing et al. 2003). The relationship between TFPI synthesis and lipid
metabolism is controversial (Ettelaie, Wilbourn et al. 1999; Kawaguchi, Miyao et al. 2000).
Kato et al (2002) found an inverse relationship between free TFPI level and HDL
cholesterol level.
Smoking
Nicotine induces TF expression in endothelial cells and VSMCs in cell culture studies
(Cirillo, S et al. 2006). Smoking in vivo is associated with increased plasma TF activity and
a strong correlation has been observed between the number of cigarettes smoked and
plasma TF expression (Sambola, Osende et al. 2003).
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1.15. TF IN CORONARY ARTERY DISEASE (CAD)
Coronary artery disease (CAD) is the result of chronic inflammation within the arterial wall,
the pathogenesis of which is still not completely understood (Ross 1999). Several
inflammatory markers have been associated with increased risk of CAD. Recently TF,
which activates coagulation and affects inflammation has been implicated in the
pathogenesis of CAD (Moons, Levi et al. 2002; Steffel, Luscher et al. 2006). TF is
extensively expressed in all stages of atherosclerotic lesions (Landers, Gupta et al. 1994;
Hatakeyama, Asada et al. 1997). TF antigen, and activity have been detected in various cell
types within plaque including endothelial cells, VSMCs, monocytes and foam cells
(Wilcox, Smith et al. 1989; Marmur, Thiruvikraman et al. 1996; Hatakeyama, Asada et
al. 1997). Tissue factor, probably of macrophage origin, has been found in abundance in the
extra cellular matrix of the necrotic core of atherosclerotic plaques (Thiruvikraman, Guha
et al. 1996; Toschi, Gallo et al. 1997). TF in atherosclerotic plaques may play a major role
in the initiation of thrombus formation. Fibrin deposition in the atherosclerotic intima is
occasionally located around macrophages and VSMCs, which express TF in abundance
(Ichikawa, Nakagawa et al. 1996). In human coronary atherectomy specimens, TF
antigen concentration and activity were found to be higher in patients with myocardial
infarction or unstable angina (associated with increased plaque thrombogenicity)
compared to those with stable angina (Annex, Denning et al. 1995; Marmur,
Thiruvikraman et al. 1996; Ardissino, Merlini et al. 1997).
Significantly higher levels of circulating soluble TF are found in patients with acute MI or
unstable angina compared to patients with stable angina or healthy controls (Suefuji,
Ogawa et al. 1997; Misumi, Ogawa et al. 1998; Cunningham, Romas et al. 1999; Mallat,
Benamer et al. 2000). Vascular smooth muscle cells, circulating leukocytes and
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aggregating platelets may be a source of elevated circulating TF level (Suefuji, Ogawa et al.
1997). Plaque rupture may also contribute to elevated plasma TF level by exposing highly
procoagulant plaque content to the circulation (Mallat, Benamer et al. 2000). In patients with
acute myocardial infarction elevated TF level may result from release of TF containing
microparticles from the lipid core following endothelial erosion of athesclerotic lesions
(Virmani, Kolodgie et al. 2000).
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1.16. TFPI IN CORONARY ARTERY DISEASE (CAD)
Atherosclerotic plaque disruption, complicated by local thrombosis, is considered to be the
key factor in the development of acute coronary syndrome including unstable angina and
myocardial infarction. Several reports have demonstrated co- localization ofTFPI and TF
in atherosclerotic plaques, suggesting a role for TFPI in the modulation of plaque
thrombogenicity by attenuating TF activity (Caplice, Mueske et al. 1998; Kaikita, Takeya
et al. 1999; Crawley, Lupu et al. 2000). Over expression of TFPI reduces thrombus formation
after vascular injury and reduced endogenous TFPI activity may enhance thrombus
formation. Studies have demonstrated beneficial effects of recombinant TFPI on TF
induced arterial thrombosis (Haskel, Torr et al. 1991; Badimon, Lettino et al. 1999; Roque,
Reis et al. 2000). Although the physiological aspects of TFPI suggest that its potential
deficiency should lead to thrombosis (Bajaj, Birktoft et al. 2001), the relationship of TFPI
and atherothrombosis is less clear. The Prospective Epidemiological study of Myocardial
Infarction (PRIME) demonstrated the association of low free TFPI levels with an
increased risk of coronary events (Morange, Simon et al. 2004). However elevated
plasma TFPI levels have been reported in patients with ischaemic heart disease (Moor,
Hamsten et al. 1994; Falciani, Gori et al. 1998; Soejima, Ogawa et al. 1999). Soejima et al
reported increased plasma free TFPI levels in patients with unstable angina, and its
association with an adverse outcome. The Athero Gene study also demonstrated a raised
plasma free TFPI level in acute coronary syndrome when compared to those with stable
angina or healthy controls (Morange, Blankenberg et al. 2007). Free plasma TFPI has
been suggested to be a marker of myocardial damage in coronary disease. TFPI
concentrations are markedly increased in patients with myocardial infarction (especially
those with ST elevation) and there is a strong correlation of TFPI levels with troponin
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levels in patients with acute coronary syndrome (Morange, Simon et al. 2004; Morange,
Blankenberg et al. 2007).
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1.17. TF AND TFPI IN PERIPHERAL ARTERIAL DISEASE (PAD)
In contrast to TF pathway in CAD, limited data exists on the relationship of TF and TFPI in
patients with peripheral arterial disease (PAD). PAD is known to confer a prothrombotic
state, with an intimate relationship between thrombogenesis and atherogenesis (Makin,
Silverman et al. 2002). Recent evidence suggests TF to be considered as one possible index
of a prothrombotic state (Makin, Chung et al. 2003). Increased level of TF have been
reported in patients with PAD compared to healthy controls (Blann, Amiral et al. 2000;
Makin, Chung et al. 2003). In contrast to reports of increased levels of TFPI activity in
coronary artery disease, Blann et al. found lower level of total TFPI in patients with PAD
compared to healthy controls (Sandset, Sirnes et al. 1989; Falciani, Gori et al. 1998; Blann,
Amiral et al. 2000). Blann et al suggest low TFPI level to be at least in part responsible for
a increased tendency of thrombosis in patients with PAD.
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1.18. TF AND TFPI IN RESTENOSIS FOLLOWING ANGIOPLASTY (PTA)
The mechanical injury sustained during percutaneous transluminal angioplasty
provokes a distinct biological event, which is different from spontaneous atherosclerosis
(Orford, Selwyn et al. 2000). Angioplasty induced vascular injury may lead to
neointimal hyperplasia which involves platelet deposition, VSMC proliferation and
migration, and synthesis and deposition of extra cellular matrix. The mechanical injury
may also lead to negative vascular remodelling with vessel constriction and reduced
vessel lumen due to adventitial scarring. Thrombus formation and the inflammatory process
play a crucial role in this vascular response to arterial balloon dilatation (Davis, Fischer et al.
2003). Inflammation can cause local thrombosis, which may again amplify inflammation
(Libby and Simon 2001).
Experimental evidence suggests that TF may play an important role in the pathogenesis of
restenosis following percutaneous transluminal angioplasty or bypass operations. In vitro
studies have demonstrated up regulation of TF in the arterial wall and raised TF levels in
the developing neointima following balloon angioplasty (Hatakeyama, Asada et al. 1998;
Giesen, Fyfe et al. 2000; D'Andrea, Ravera et al. 2003). TF has been demonstrated to
contribute to the inflammatory response, thrombus propagation, vascular smooth
muscle cell migration and proliferation. Each of these processes are considered to be
important steps in genesis of restenosis (Sato, Asada et al. 1996; Giesen, Rauch et al.
1999; Chu 2005). In animal studies, TF inhibition reduces intimal hyperplasia following
angioplasty (St Pierre, Yang et al. 1999; Roque, Reis et al. 2000). Human studies have
predominantly focussed on the role of TF in restenosis following coronary percutaneous
transluminal angioplasty (PTA). Marcucci et al observed a positive correlation between
plasma TF level and angiographically documented clinical recurrences after coronary
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PTA in ischaemic heart disease patients (Marcucci, Prisco et al. 2000). Mizuno et al
demonstrated that elevated levels of TF antigen in the coronary sinus blood after coronary
PTA in IHD patients are associated with late restenosis (Mizuno, Ikeda et al. 2001).
Extending this observation further, Tutar et al demonstrated that whole blood TF
procoagulant activity was a marker for restenosis following coronary PTA and stent
implantation (Tutar, Ozcan et al. 2003).
TFPI represents the only physiological inhibitor of the TF: Factor VII complex and has
been implicated in the inhibition of neointima formation following balloon angioplasty in
animal models (Jang, Guzman et al. 1995; Brown, Kania et al. 1996). TFPI has been
suggested to inhibit neointimal growth following angioplasty by inhibiting TF induced
thrombus propagation and by inhibiting VSMC proliferation and migration (Sato, Asada et
al. 1997; Sato, Kataoka et al. 1999; Yutani, Imakita et al. 1999).
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Chapter 2. Materials and Methods
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2.1. Aim of the study
1) To determine variation in symptomatology and disease progression in unilateral
claudicants awaiting femoropopliteal PTA in the waiting list for more than 3 months.
2) To determine the association between plasma TF, TFPI concentration and the development
of restenosis in unilateral claudicants following femoro popliteal percutaneous transluminal
angioplasty (PTA).
2.2. Design of the study
2.2.1. Ethical approval
A full study protocol was submitted to the Local Regional Ethics Committee- Hull and East
Riding and to the NHS Research and Development Department of the Hull and East
Yorkshire NHS Trust. Full ethical approval was obtained from both organisations before the
start of the study.
2.2.2. Research staff
The staff involved in the study comprised of one Professor of Vascular Surgery, one
consultant Vascular Surgeon (Senior lecturer), one Biomedical Scientist, one Vascular
technician and the author of this thesis.
2.2.3. Patient selection
1) For assessing variation in symptomatology and disease progression 47 patients were
identified that had been waiting for elective femoropopliteal PTA more than 3 months.
2) For study to determine association between plasma TF, TFPI and restenosis following
femoropopliteal PTA, unilateral claudicants scheduled to undergo femoropopliteal
angioplasty were included in the study after obtaining informed written consent.
2.2.4. Control population
Ten age and sex matched control subjects with normal ankle: brachial pressure indices
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(ABPI) were recruited from patients attending for hernia repair, or other minor
operations, or healthy hospital staff for measurement of plasma TF and TFPI and
written informed consent was obtained.
2.2.5. Exclusion criteria’s
1. Patients with recent M.I. (<3 months)
2. Disseminated malignancy
3. Systemic sepsis
4. Acuteor chronic renal impairment.
2.2.6. Sample size calculation
From previously published work it is known that the incidence of restenosis following
femoropopliteal angioplasty ranges from 30-40 %. The sample size was calculated
using base line mean TF concentration and a 6 month restenosis rate of 30% in
previously published study (Tutar, Ozcan et al. 2003). The minimum number of patients
needed for 80% power was 46. Allowing for the risk of dropouts and interventional
complications the total target was set at 52 patients.
2.2.7. Patient recruitment
1) For assessing variation in symptomatology and disease progression, 47 patients were
identified that had been waiting for elective femoropopliteal PTA more than 3 months.
2) For study to determine association between plasma TF, TFPI and restenosis following
femoropopliteal PTA, all patients with unilateral claudication scheduled to undergo
femoropopliteal PTA were considered for the study. Patients who met the criteria for the
study were approached by the author. The purpose of the study and the follow up schedule
were explained to the patient. Patients’ questions were answered and they were provided
with a patient information leaflet. If the patient then elected to participate in the study,
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written consent was obtained.
2.2.8. End-point
The end point for this study was restenosis of the angioplastied segment at 6 months.
2.3. Intervention
a) For study to determine variation in symptomatology and disease progression in unilateral
claudicants awaiting femoropopliteal PTA in the waiting list:
1) Case note review: A comprehensive case note review was performed for all patients.
Data collected included age, gender, vascular symptoms, patient reported walking
distance (PRWD), ankle brachial pressure index at rest (ABPI), initial duplex assessment,
and date of acceptance to the PTA waiting list.
2) Reassessment: A clinical and imaging assessment was performed in a consultant led
clinic assisted by an experienced vascular technologist. and a research fellow following
informed consent. A proforma was completed for each patient. Clinical and imaging data
was recorded in the proforma including claudication symptomatology (stable, improved
or deteriorated), co morbidities, and patient reported walking distance (PRWD). Ankle
Brachial pressure indices were measured at rest (ABPI) and an arterial duplex was
performed on the symptomatic limb by an experienced vascular scientist and compared
with the initial duplex assessment to assess disease progression. All arterial lesions were
graded according to TransAtlantic Inter-Society Consensus (TASC) guideline.
b) For study to determine the association between plasma TF and TFPI concentration and the
development of restenosis:
2.3.1 Pre angioplasty protocol for the study group
Patients enrolled for the study underwent assessment in the vascular research laboratory at
Hull Royal infirmary. A proforma was completed for patients’ symptom and risk factors
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for peripheral vascular disease (hypertension, diabetes, smoking, hyperlipidemia, cardiac
disease). Resting ankle brachial pressure index (or toe brachial pressure index in diabetics)
and duplex ultrasound assessment of the symptomatic limb were performed and recorded
in the proforma. Venous blood samples were obtained from the study group and
centrifuged to obtain plasma which was stored in aliquots at -800 C for future
measurement of TF and TFPI.
2.3.2. Percutaneous transluminal angioplasty: PTA were performed by experienced
consultant interventional radiologists with no deviation from a standard protocol. At the end
of the procedure, the radiologist marked the site of the angioplastied arterial segment on the
patients skin. This angioplastied segment was then accurately recorded in the proforma by
measuring the distance from a fixed bony point.
2.3.3. Post angioplasty follow-up
As shown in Figure 5, all patients were assessed 24 hours following femoropoliteal
angioplasty. Only patients with a haemodynamically successful PTA with no significant
residual stenosis were followed up at 1, 3, and 6 months. Haemodynamic success was
defined by an increase in ankle brachial pressure index by at least 0.1 following
angioplasty (Rutherford 1997). A significant residual stenosis was defined as as peak
systolic velocity at the angioplastied segment greater than 2.5 times that of the adjacent
normal arterial segment at 24hours post PTA. Assessment at 1, 3, and 6 months entailed
clinical appraisal, blood sampling for TF and TFPI measurement and colour Duplex
ultrasound imaging for detection of restenosis. Restenosis was defined as peak systolic
velocity at the angioplastied segment greater than 2.5 times that of the adjacent normal
arterial segment.
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Figure 5. Post angioplasty follow-up protocol
Claudicants
PTA ____
Clinical and imaging assessment at day 1 PTA
Haemodynamic success and no residual Haemodynamic failure* and or
stenosis on duplex at PTA site residual stenosis on duplex at PTA
site †
Blood sampling for TF and TFPI, Exclusion from study
Clinical and imaging study at 1,
3, and 6months
* No change In ABPI or an increase in ABPI of < 0.1
† Peak systolic velocity of angioplastied segment >2.5 times that of
adjacent normal segment.
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2.3.4. Blood Sampling and storage
Venous blood samples were collected from basilic vein in vacutainer test tubes
containing sodium citrate. The blood samples were immediately centrifuged for 15
minutes at 3000rpm at 40C. The plasma thus obtained was stored in aliquots at –800C
for subsequent analysis.
2.3.5. Measurement of plasma TF
The plasma TF was measured by a highly sensitive enzyme linked immunosorbent
assay (ELISA).The sandwich variant of the ELISA was used for measurement of
plasma TF (Affinity Biological Inc).
Principle of Sandwich-style ELISA for TF (Fig.6)
Monoclonal antibody to Tissue Factor (TF) was coated onto the wells of a micro titre
plate. Any remaining binding sites on the plastic wells were blocked with an excess of
bovine serum albumin. The plates were washed and biological fluids containing TF were
applied. The coated antibody captured the TF in the sample. After washing the plate to
remove unbound material, a peroxidase conjugated polyclonal antibody to TF was
added to the plate to bind to the captured TF. After washing the plate to remove unbound
conjugated antibody, the peroxidase activity was expressed by incubation with o-
phenylenediamine (OPD). After a fixed development time the reaction was quenched
with the addition of H2SO4 and the colour produced was quantified using a micro plate
reader. The colour generated is proportional to the concentration of TF present in the
sample.
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Figure 6. Principle of Sandwich ELISA
R. A. Goldsby, T. J. Kindt, B. A. Osborne, Kuby Immunology, 4th ed. (W. H. Freeman
and Company, 2000), p. 162.
Antibody
coated well
Antigen binds
to antibody
A second ant ibod y
Linked to enzyme binds
to immobilized antigen
Added substrate is
converted by
enzyme in to
coloured product
In the Sandwich ELISA technique, Plate is coated with known amount of capture antibody
and any nonspecific binding site is blocked with blocking buffer. An antigen containg
sample is added to the plate to allow the antigen to bind to the capture antibody. Plate is
then washed to remove unbound antigens. A detecting antibody is then added, which
binds to the antigen. An Enzyme-linked secondary antibody is then added, that binds to
the detecting antibody. A substrate is added, and is converted by the enzyme to a
detectable coloured form.
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Materials and reagents for assay
1. Capture Antibody (Affinity BiologicalsTM)
2. Detecting Antibody (Affinity BiologicalsTM)
3. Purified recombinant apo-tissue factor (American Dignostica)
4. Coating Buffer: 50 mM Carbonate(pH 9.6)
5. PBS (pH7.4)
6. Wash Buffer: PBS-Tween (pH 7.4)
7. Blocking Buffer: PBS-BSA (pH 7.4)
8. Sample Diluent: HBS-TX100 (pH 7.2)
9. Conjugate Diluent: HBS-BSA-T20
10. Substrate Buffer (pH 5.0)
11. OPD Substrate (Sigma # P-69 12)
12. Stopping solution: 2.5M H2SO4
13. 96 well microplates, microplate washer, microplate reader
Assay Procedure:
1. Coating of plates:
Capture antibody was diluted to 1/100 in coating buffer and immediately 100 μl added
to every well in the plate. The plate was then incubated overnight at 4oC.
2. Blocking:
Contents of plate were emptied and 150 μl of blocking buffer added to every well and
incubated for 90 minutes at 22oC. Plate was then washed 3 times with wash buffer.
3. Preparation of Reference Standards and Test Samples:
Reconstituted the vial of recombinant apo-TF to 10 µg/ml in water (unused material
frozen in aliquots and stored at -70oC). The stock TF 1/100 was further diluted in
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sample diluent to achieve a final concentration of 100 ng/ml, then serial 1/2's down to
1/3200 (3.13 ng/ml). Test samples were diluted 1/4 and 1/8. All dilutions were made in
sample diluent. 100 μl/well was applied and the plate was incubated at 22oC for 60
minutes. The plate was then washed three times with wash buffer.
4. Detecting Antibody:
Detecting antibody was diluted 1/100 in conjugate diluent. 100 μl of this was then applied
to each well and incubated the plate at 220C for 60 minutes. The plate was then washed three
times with wash buffer.
5. OPD Substrate:
100 μl of freshly prepared OPD substrate was applied to every well. Colour was
allowed to develop for 5-10 minutes and then the colour reaction was stopped with
addition of 50 μl/well of 2.5 M H2SO4. The plate was then read at wavelength of
490 nm. 6. Calculation of Results:
The standard curve was constructed by plotting the mean absorbance value for each TF
standard versus the corresponding concentration of TF in ng/ml. The TF concentrations
for diluted samples were interpolated directly from the standard curve. A standard curve
was generated each time the assay was performed.
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2.3.6. Measurement of plasma TFPI
The plasma TFPI was measured by a highly sensitive enzyme linked immunosorbent
assay (American Diagnostica Inc.) This ELISA detects both intact and truncated forms of
TFPI as well as complexes with tissue Factor (TF) and factor VIIa (TF/VIIa/TFPI).
Principle of Sandwich-style ELISA for TFPI
The IMUBIND Total TFPI ELISA is a "sandwich" ELISA employing a rabbit antihuman
TFPI polyclonal antibody as the capture antibody. Specificity of the capture antibody for
native, complexed and truncated TFPI was confirmed by Western blot analysis, visualizing
a single band at 34 kDa, corresponding to the mobility of intact native TFPI and
visualizing a single band at 21 kDa, corresponding to the mobility of a truncated form of
TFPI. Diluted plasma samples incubated in micro-test wells precoated with this capture
antibody. TFPI is detected using a biotinylated monoclonal antibody specific for the
specific domain of TFPI. The subsequent binding of the streptavidin conjugated
horseradish peroxidase (HRP) completes the formation of the antibody enzyme
detection complex. The addition of TMB substrate and its subsequent reaction with HRP
provided a blue colour. Sensitivity was increased by addition of a 0.5M sulphuric acid stop
solution, yielding a yellow colour. TFPI levels were determined by measuring sample
solution absorbance at 450 nm and comparison against those of a standard curve
developed using native TFPI.
Materials and reagents for assay
1. TFPI Standard, 5 ng/mL (lyophilized)
2. TFPI Depleted Plasma (lyophilized)
3. TFPI Reference Plasma (lyophilized)
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4. Detection Antibody, biotinylated anti-human TFPI F (ab') 2 (lyophilized)
5. Enzyme Conjugate, Streptavidin-horseradish peroxidase
6. Enzyme Conjugate Diluent (lyophilized)
7. TMB substrate
8. Wash Buffer (pH 7.4)
9.0.5M H2SO4
10. Bovine Serum Albumin (BSA, e.g. Sigma A-7030)
11. Micro-test plate reader, 6 x 16 well precoated micro-test strips with holder and lid
Sample preparation
1. Frozen plasma samples collected from the study group were thawed at 37°C for 15
minutes.
2. These plasma samples and the TFPI reference Plasma were diluted 1:40 in Sample
Buffer.
Assay procedure
Day one
The precoated micro-test strips were placed on a plate holder and 100 μL of TFPI
Standard, TFPI Reference Plasma or diluted sample were added to micro-test wells,
covered with lid and incubated overnight at +4°C. Measurements were performed in
duplicate.
Day 2
1. The wells were washed 4 times with Wash Buffer.
2. 100 μl of Detection Antibody was added to each well, covered with lid and
incubated for 1 hour at room temperature.
3. Wells were washed 4 times with Wash Buffer.
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4. 12 μL of Enzyme Conjugate was added to 12 mL of Enzyme Conjugate Diluent.
100 microlitre of diluted enzyme conjugate was added to each well, covered with lid and
then incubated for one hour at room temperature.
5. Wells were washed 4 times with Wash Buffer.
6. 100 μL of Substrate solution was added to each well, and covered with lid and
incubated for 20 minutes at room temperature. A blue colour developed.
7. The enzymatic reaction was stopped by adding 50 μL of 0.5M H2SO4. The solution
colour turned yellow. The absorbances were read on a micro-test plate reader at a
wavelength of 450 nm within 30 minutes. The background average of the blanks was
deducted from the standards and sample readings.
Calculation of results
The standard curve was constructed by plotting the mean absorbance value for each TFPI
standard versus the corresponding concentration of TFPI in ng/mL(Figure 7). The TFPI
concentrations for diluted samples were interpolated directly from the standard curve. A
standard curve was generated each time the assay was performed.
TFPI concentrations obtained for each test sample, as interpolated from the standard
curve were averaged and multiplied by the dilution factor of the sample(40 in this study)
to calculate the TFPI concentration of the original sample.
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Figure 7. Standard curve for TFPI measurement
Figure shows a standard curve used in quantitave ELISA used for measurement
of plasma TFPI. The standard curve was constructed by plotting the mean
absorbance value for each TFPI standard versus the corresponding concentration
of TFPI in ng/mL followed by plotting a curve through the points. Microsoft
excel 2003 was used for plotting the standard curve in our study.
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2.3.7. Internal validation of effect of storage on plasma TF and TFPI level
Plasma samples were stored at -800C and analysed in batches at a later date. Internal
validation was performed to observe the effect of storage on plasma TF and TFPI levels.
Separate batches of stored plasma samples of ten individuals were analysed for TF and
TFPI on fresh samples and at one month and two months after storage.
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2.4. Statistical analysis
2.4.1. For determination of variation in symptomatology and disease progression in
claudicants awaiting PTA: for more than 3 months: All continuous variables were
reported as median values with interquartile range (IQR). Discrete variables are presented
as counts and percentages. Mann-Whitney U tests were used to compare unpaired
continuous variables and Wilcoxon paired tests were used to analyze paired continuous
variables. A two sided p-value <0.05 was considered statistically significant. All
statistical analysis was performed using SPSS for Windows (version 11.5, SPSS Inc., IL,
USA).
2.4.2. For determination of effect of storage on plasma TF and TFPI levels: The averages
of assay values for TF and TFPI for each ten individuals were analysed using Friedman’s
test. The tests were considered significant if p value was less than 0.05.
2.4.3. For determination of the association between plasma TF and TFPI concentration and
the development of restenosis: Plasma TF and TFPI concentrations were reported as median
values with interquartile range (IQR). Nonparametric ANOVA test was used to compare
plasma TF or TFPI concentration with occurrence of restenosis. The association of plasma
TF and TFPI with occurrence of restenosis was analysed by Mann Whitney U test.
Analysis for the difference of TF and TFPI levels from the pre PTA baseline levels at
different intervals following PTA were done separately for the patent and restenotic groups
using Wilcoxon’s sign rank test for two paired samples. The tests were considered
significant if p value was less than 0.05. All statistical analysis was performed using SPSS
for Windows (version 11.5, SPSS Inc., IL, USA).
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Chapter 3. Results
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3.1 VARIATION IN PATIENT SYMPTOMATOLOGY AND DISEASE
DISTRIBUTION IN CLAUDICANTS AWAITING FEMOROPOPLITEAL PTA
3.1.1 Epidemiology
Forty seven claudicants (M: F; 34:13), median age 69 (interquartile range 46-89) years
with a median waiting period of 9.6 (interquartile range 4-21) months for underwent the
reassessment. Patients’ epidemiological characteristics, smoking habit and associated co
morbidities based on case note review and initial assessment are summarised in Table 4.
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Table 4. Study population characteristics and co morbidities
Median Age (IQR), years 69(46-89)
No. of patients Percentage
Gender
Male 34 72.3
Female 13 27.7
Hypertension 30 63.8
Diabetes 9 19.1
Cardiac disease 13 27.7
Renal disease 0 0
Carotid disease 9 19.1
COPD* 10 21.2
Arthritis 11 21.2
Tobacco use 29 61.7
*Chronic obstructive pulmonary disease
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3.1.2. Comparison of symptom and disease progression at reassessment of
claudicants awaiting PTA.
At reassessment, 30 (64%) patients were found to be symptomatically stable whilst
10(21%) and 7(15%) had improved or deteriorated respectively from baseline.
Duplex USS performed at reassessment demonstrated 9 (19%) TASC A, 15 (32%) TASC
B, 19 (40%) TASC C and 4 (9%) TASC D lesions of the index limb (planned for PTA).
Comparison with baseline duplex ultrasound demonstrated a disease progression in
9(19%) patients. The majority remained stable (Table 5). There was a significant
association between waiting time and change in symptomatology (p=0.008, Mann
Whitney U test); however no significant association was found between the waiting time
and change in disease pattern at baseline and reassessment (p=0.88, Mann Whitney U
test).
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Table 5. Waiting period, symptom and disease progression at reassessment of
claudicants awaiting PTA.
Median waiting period (IQR), months 9.6 (4- 21)
Symptom at assessment No. of patients Percentage
Stable 30 64.0
Improved 10 21.3
Deteriorated 7 14.8
Disease assessment on duplex USS
Stable 38 80.9
Deteriorated 9 19.1
* Data reported as median and interquartile range (IQR).
Table showing comparison of claudication symptom and duplex USS assessment in
patients awaiting femoropopliteal PTA at baseline and at reassessment.
At reassessment, 64% patients were found to be symptomatically stable whilst 21% and
15% had improved or deteriorated respectively from baseline.
Comparison of duplex USS finding at baseline and at reassessment showed disease
progression in 19% patients while majority remained stable. There was a significant
association between waiting time and change in symptomatology (p=0.008, Mann
Whitney U test); however no significant association was found between the waiting time
and change in disease pattern at baseline and reassessment (p=0.88, Mann Whitney U
test).
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3.1.3. Comparison of Walking distance and ABPI in claudicants awaiting PTA at
baseline and reassessment (Table 6)
The median baseline patient reported walking distance (PRWD) was 100m (interquartile
range 0-400) while at the time of reassessment, the median PRWD was 100m
(interquartile range 10-1500) (p=0.19, Mann Whitney U test).
The median resting ABPI was 0.65 (interquartile range 0.41-0.98) at baseline and 0.71
(interquartile range 0.48-1.09) at reassessment (p=0.06, Mann Whitney U test).
Claudicants who remained stable, demonstrated stable PRWD and ABPI at reassessment.
Claudicants who improved symptomatically, demonstrated significant improvement in
PRWD and ABPI at reassessment (p<0.05, Mann Whitney U test) . Claudicants who
symptomatically deteriorated, demonstrated a significant deterioration in PRWD but no
significant deterioration in ABPI at reassessment.
83
Table 6. Comparison of Walking distance and ABPI in patients with stable
claudication, clinical improvement, and clinical deterioration at baseline and
reassessment.
Baseline At assessment P-value
(Mann Whitney U)
Patients with stable claudication (n= 30)
Walking distance 100(20-400) 100(50-800) 0.37
ABPI 0.70(0.42-0.98) 0.66(0.48-0.99) 0.89
Patients with clinical improvement (n=10)
Walking distance 100(20-400) 350(50-1500) 0.018
ABPI 0.61(0.41-0.72) 0.84(0.65-1.09) 0.009
Patients with clinical deterioration (n=7)
Walking distance 200(100-400) 50(10-200) 0.04
ABPI 0.60(0.53-0.75) 0.68(0.58-0.82) 0.59
*Data reported as median and interquartile range (IQR).
Table showing comparison of patient reported walking(PRWD) distance and ABPI in
claudicants who remained symptomatically stable, improved or deteriorated at
reassessment. Claudicants who remained stable, demonstrated stable PRWD and ABPI at
reassessment. Claudicants who improved symptomatically, demonstrated significant
improvement in PRWD and ABPI at reassessment (p<0.05, Mann Whitney U test) .
Claudicants who symptomatically deteriorated, demonstrated a significant deterioration in
PRWD but no significant deterioration in ABPI at reassessment.
84
3.2 PLASMA TF, TFPI AND RESTENOSIS FOLLOWING
FEMOROPOPLITEAL PTA
3.2.1. Epidemiology
52 claudicants (M: F; 3:1), median age 69 (interquartile range 46-86) years underwent
initial assessment prior to angioplasty. Patients’ epidemiological characteristics,
smoking habit and associated co morbidities are summarised in Table 7.
3.2.2. Patient symptomatology and lesion characteristics
The median patient reported walking distance (PRWD) of the study group was 100
(interquartile range 50-180) meters and the median resting ABPI was 0.65
(interquartile range 0.50-0.83). Duplex performed at initial assessment demonstrated 16
(30.8%) TASC A lesions, 19(36.5%) TASC B lesions, and 17 (32.7%) TASC C lesions of
the index limb planned for PTA (Table 8).
85
Table 7. Demographic profile of the study population
Median Age (IQR), years 69(46-82)
Male: Female 3:1
No. of patients Percentage
Hypertension
Diabetes
Cardiac disease
Carotid disease
COPD*
Tobacco use
Hyperlipidaemia
26
7
11
2
8
28
17
53.1
14.3
22.4
4.1
16.3
57.1
34.7
*Chronic obstructive pulmonary disease
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Table 8. TASC grading for femoropopliteal disease of the index limb*
TASC grade Lesion Characteristics Percentage study
population
TASC A  Single stenosis up to 3 cm; Not at SFA origin or distal
popliteal artery.
30.8%
TASCB  Single stenosis/occlusion 3-5 cm; not at distal popliteal
artery.
 Heavy calcified stenosis up to 3 cm.
 Multiple lesions, each < 3 cm
 Single/ Multiple lesions in absence of continuous tibial
runoff.
36.5%
TASC C  Single stenosis/occlusion > 5 cm
 Multiple Single stenosis/occlusions each 3-5 cm with or
without heavy
calcification.
32.7%
TASC D Complete CFA or SFA occlusions or complete popliteal and
proximal trifurcation occlusions
0
* TASC Working Group. TransAtlantic Inter-Society Consensus
(TASC). J Vasc Surg, 2000.
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3.2.3. Femoropopliteal PTA and outcome in the follow up assessments:
Of the 52 patients enrolled in the study, 49 claudicants underwent successful
femoropopliteal PTA.Technical failure occurred in three (5.7%) patients, due to inability
to cross the lesion with a guide wire. Majority of the angioplatied segments were were
located in the SFA. ABPI and duplex assessment of the angioplastied limb at 24 hours
following PTA, identified thrombotic occlusion in two patients. Overall 47 patients hence
underwent further follow up for detection of restenosis. 16 claudicants (32.6%) developed
restenosis within 6 months following angioplasty. Based on ankle brachial index,
haemodynamic failure was noted in 19 patients. The relationship of the PTA type, restenosis
and haemodynamic failure are summarised in Tables 9-13.
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Table 9. Femoropopliteal Percutaneous Ttransluminal Angioplasty in the study
group
Procedural success
Haemodynamic success following PTA*
49
47
PTA type No. of patients Percentage
Superficial femoral artery
(SFA)
SFA- Popliteal
Popliteal(POP)
SFA/POP with TPT **
22
17
5
5
44.9
34.7
10.2
10.2
* Defined as an increase in the ABPI by at least 0.1 at 24 hours following PTA
** Tibio peroneal trunk
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Table 10. Duplex USS assessed outcome of angioplastied limb following
femoropopliteal PTA
Follow up
PTA Patent Restenosis**
Thrombotic
occlusion* Total
SFA 15 7 0 22
SFAPOP 11 5 1 17
POP 2 3 0 5
SFA/ POP-TPT 3 1 1 5
Total 31 16 2 49
The restenosis rate in patients who underwent SFA PTA only and those undergoing
SFA and popliteal artery PTA were comparable (31% vs 29%). Patients undergoing
popliteal artery PTA had the highest incidence of restenosis (60%). Although 20% of
patients undergoing SFA/ POP-TPT developed restenosis, 20% had post procedural
thrombotic occlusion.
* Thrombotic occlusion within 24 hour following PTA; Not followed up further.
** Restenosis as identified on duplex imaging.
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Table 11. Haemodynamic outcome following femoropopliteal PTA
Haemodynamic outcome Total
Haemodynamic
success
Haemodynamic
failure*
Early
haemodynamic
failure**
SFA 15 7 0 22
SFAPOP 8 8 1 17
POP 2 3 0 5
SFA/POP-TPT 3 1 1 5
Total 28 19 2 49
Overall haemodynamic failure following PTA was 40%. Majority of the haemodynamic
failures occurred in patients undergoing popliteal or popliteal and tibioperoneal trunk
(TPT) PTA. 2 patients had thrombotic occlusion following PTA and were not followed
up for restenosis.
* > 0.1 reduction of ABPI from the post PTA ABPI (Rutherford et al. 1997).
** Thrombotic occlusion within 24 hour following PTA; not followed up further.
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Table 12. TASC grading and restenosis following femoropopliteal PTA
TASC A TASC B TASC C Total
Patent 11 13 7 31
Restenosis 5 5 6 16
Total 16 18 13 47
Highest incidence of restenosis was seen in claudicants undergoing PTA of TASC C
lesions. Outcome following PTA of TASC A and TASC B lesions were comparable.
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Table 13. Correlation between restenosis and haemodynamic outcome* following
femoropopliteal PTA
Haemodynamic outcome
Success Failure Total
Duplex USS Patent
follow up
20 11 31
Restenosis 8 8 16
Total 28 19 47
Haemodynamic outcome at follow-up intervals, after PTA did not correlate with the
occurrence of restenosis as identified by duplex ultrasound. 35% (11/31) of the
claudicants whose PTA site remained patent at 6 month had haemodynamic failure. 50 %
(8/16) of the claudicants who developed restenosis did not have haemodynamic failure.
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3.2.4. Effect of plasma sample storage on TF and TFPI level
As samples were analysed in batch, the results for separate bath of stored samples were
analysed on fresh samples and after storage for one and two months to observe the effect
of storage on plasma TF and TFPI levels.
The three averages of the two assay values for TF for each 10 individuals, analysed using
Friedman’s test showed no statistically significant change of plasma TF levels over time
during storage (p= 0.721; Friedman’s test; Fig. 8). Similar analysis for plasma TFPI also
did not show significant change over time (p= 0.368; Friedman’s test ; Fig. 9).
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Fig. 8. Plasma TF levels at different time points during storage at -800C
Fig 8 shows a line chart showing plasma TF levels at different interval during storage of
plasma samples at -800C. No statistically significant change of TF levels was observed
over time (p= 0.721, Friedman’s test).
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Fig. 9. Plasma TFPI levels at different time points during storage at -800C
Fig 9 shows a line chart showing plasma TF levels at different interval during storage of
plasma samples at -800C. No statistically significant change of TF levels was observed
over time (p= 0.368, Friedman’s test).
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3.2.5. Plasma TF levels in healthy control and claudicants at baseline.
Plasma TF levels in healthy controls and in the claudicants before PTA are shown in
Figure 10. Claudicants demonstrated significantly higher baseline plasma TF than control
subjects (p<0.05, Mann-Whitney U). The median plasma TF concentration in
claudicants was 3.3ng/ml (interquartile range 1.3-7.1). The plasma TF concentration in
healthy controls was median 1.2 ng/ml (interquartile range 0.4-1.8).
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Figure 10. Plasma TF in healthy controls and claudicants
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Box whisker plot showing difference between plasma TF concentration in healthy
controls and claudicants. The box represents the interquartile range (IQR) and the
horizontal line in the box being the median value. The whiskers represent the
minimum and maximum range of the data. Claudicants demonstrated significantly
higher baseline plasma TF than control subjects (p<0.05, Mann-Whitney U).
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3.2.6. Baseline (pre PTA) Plasma TF levels in claudicants undergoing femoro-
popliteal PTA and its relationship with restenosis.
In claudicants, baseline TF levels were significantly higher in those who developed
restenosis following PTA than those who did not (p=0.03, Mann-Whitney U) – Figure
11. The median baseline value of plasma TF concentration in claudicants who remained
patent following PTA was 1 .64ng/ml (1.3-7.2), whilst in those developing restenosis the
median baseline plasma TF concentration was 6.96ng/ml (3.36-179).
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Fig. 11. Baseline plasma TF levels in claudicants underoing femoropopliteal PTA
and its relationship with restenosis.
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Box whisker plot showing difference between plasma TF concentration in claudicants
undergoing femoropopliteal PTA. The box represents the interquartile range (IQR) and the
horizontal line in the box being the median value. The whiskers represent the minimum
and maximum range of the data. The baseline TF levels were significantly higher in those
who developed restenosis following PTA than those who did not (p=0.03, Mann-Whitney
U).
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3.2.7. Changes in plasma TF concentration following femoropopliteal PTA
Plasma TF levels at baseline prior to angioplasty, and at 24 hours, 1 month, 3 months and 6
months following angioplasty are displayed in Table 14 and Figure 12. Plasma TF
concentrations at all follow up visits were raised in patients who restenosed, compared to
those who remained patent. The differences between those who restenosed and those who
remained patent were statistically significant except at month 1 following PTA. The
difference of TF concentrations at followup intervals from the baseline levels in either
of the groups were not found to be statistically significant (p>0.05, Wilcoxon’s sign rank
test)-Table15.
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Table 14. Plasma TF levels of the Claudicants at baseline and post PTA follow up
intervals
Median TF conc. in
ng/ml (interquartile
range)
Mean rank p (Mann Whitney U)
PRE PTA
Patent 1.64 (1.3-7.2) 16.33 0.03
Restenosis 6.96 (3.3-179) 25.00
DAY1
Patent 2.40 (1.2-4.8) 16.52 0.05
Restenosis 8.44 (2.5-89.9) 24.44
MONTH 1
Patent 1.98 (0.9-4.6) 15.92 0.12
Restenosis 9.06 (0.6-121.6)) 21.89
MONTH 3
Patent 2.43 (1.2-4.7) 16.44 0.04
Restenosis 10.07 (2.5-86.3) 24.67
MONTH 6
Patent 1.99 (1.1-4.1) 16.33 0.03
Restenosis 16.16 (1.7-79.6) 25.00
Table showing plasma TF levels of patients who remained patent and those who
developed restenosis following PTA at baseline and at post PTA follow up intervals. The
TF levels were significantly higher in those who developed restenosis following PTA at all
the follow up intervals except at month 1, than those who remained patent (p<0.05, mann
whitney U test).
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Figure 12. Plasma TF concentration at baseline and at intervals following PTA
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Box and whisker plot showing baseline plasma TF concentrations in claudicants
undergoing femoropopliteal PTA and relationship with restenosis. The box represents the
interquartile range and the horizontal line in the box being the median value. The whiskers
represent the range of the data. The TF levels were significantly higher in those who
developed restenosis following PTA at all the follow up intervals except at month 1, than
those who remained patent (p<0.05, mann whitney U test).
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Table 15. The difference of TF concentrations from pre angioplasty TF levels at follow
up intervals follwing PTA.
Negative mean
ranks
Positve mean
ranks
P (Wilcoxon
sign rank test)
Day1 Patent
Restenosis
11.29
10.14
7.4
7.22
0.90
0.88
Month 1 Patent
Restenosis
9.33
9.50
8.62
7.50
0.72
0.68
Month 3 Patent
Restenosis
12.89
9.71
7.40
7.56
0.39
1.00
Month 6 Patent
Restenosis
11.36
7.12
8.12
9.88
0.23
0.57
Wilcoxon sign rank test based on ranking the difference between baseline (pre PTA)
plasma TF and TF levels at different time points following PTA. Calculations
performed separately for the groups who remained patent and the ones who developed
restenosis. The difference of TF concentrations at all followup intervals from the
baseline levels in either of the groups were not found to be statistically significant
(p>0.05, Wilcoxon’s sign rank test).
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3.2.8. Plasma TFPI in healthy controls and claudicants at baseline
Plasma TFPI levels in healthy controls and in the claudicants before PTA are shown in
Figure 13. Claudicants demonstrated significantly higher baseline plasma TFPI than control
subjects (p=0.001, Mann-Whitney U). The median plasma TFPI concentration in
claudicants was 69.97ng/ml (interquartile range 57.13- 83.11). The plasma TFPI
concentration in healthy controls was median 35.95 ng/ml (interquartile range 31.10-
44.57).
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Figure 13. Plasma TFPI in healthy controls and claudicants at baseline
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Box whisker plot showing difference between plasma TFPI concentration in
healthy controls and claudicants. The box represents the interquartile range (IQR)
and the horizontal line in the box being the median value. The whiskers represent
the minimum and maximum range of the data. Claudicants demonstrated
significantly higher baseline plasma TFPI than control subjects (p=0.001, Mann-
Whitney U).
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3.2.9. Baseline (pre PTA) Plasma TFPI levels in claudicants undergoing femoropopliteal
PTA and its relationship with restenosis
In claudicants, baseline TFPI levels were significantly higher in those who developed
restenosis following PTA than those who did not (p=0.05, Mann-Whitney U test) – Figure
14. The median value of plasma TFPI concentration in claudicants who remained patent
following PTA was 70.64ng/ml (57.3-106.25); while in those developing restenosis the
median plasma TFPI concentration was 111 .36ng/ml (80-142).
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Figure 14. Baseline plasma TFPI concentration (ng/ml) in claudiants undergoing
femoropopliteal PTA
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Box and whisker plot showing baseline plasma TFPI concentration in claudicants
undergoing femoropopliteal PTA and relationship with restenosis. The box represents the
interquartile range (IQR) and the horizontal line in the box being the median value. The
whiskers represent the range of the data. The baseline TFPI levels were significantly
higher in those who developed restenosis following PTA than those who did not (p=0.05,
Mann-Whitney U test).
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3.2.10. Change in plasma TFPI concentration following PTA
The baseline (Pre-PTA) plasma TFPI concentration was found to be significantly higher in
claudicants who developed restenosis following PTA compared to those whose angioplasty
site remained patent. Conversely, the TFPI levels were significantly lower in the
restenosis group at month 1 and 6 following PTA. The group differences did not reach
statistical significance at day 1 and month 3 following PTA (Table 16 and Fig.15). The
difference of TFPI concentrations at followup intervals from the baseline levels in
either of the groups were not found to be statistically significant (p>0.05, Wilcoxon’s
sign rank test) except the borderline significance at month 1 following PTA for the group
who did not develop restenosis (Table 17).
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Table 16. Plasma TFPI level of the Claudicants at baseline and post PTA follow up
intervals
Median TFPI conc.
in ng/ml (inter
quartile range)
Mean rank p (Mann Whitney U)
PRE PTA
Patent 70.64 (57.3-106.2) 13.31 0.05
Restenosis 111.36 (80.1-142.2) 19.73
DAY1
Patent 64.14 (2.73- 9.0 0.33
Restenosis 264.72) 23.38
56.46 (42.3-77.1)
MONTH 1
Patent 201 (73.5-272.9) 15.8 0.02
Restenosis 57.46 (46.6-86.1) 20.75
MONTH 3
Patent 169.06 (52.45-300) 16.11 0.6
Restenosis 140 (65.67-212.42) 24.38
MONTH 6
Patent 164.2 (87.6-249.1) 16.19 0.03
Restenosis 84.30 (74.6-118.6) 24.13
Table showing plasma TFPI levels of patients who remained patent and those who
developed restenosis following PTA at baseline and at post PTA follow up intervals. The
TFPI levels were significantly higher in those who developed restenosis following PTA at
baseline, but significantly lower at month 1 and month 6 following PTA (Mann whitney U
test).
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Figure 15. Change in plasma TFPI concentration following PTA
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Box and whisker plot showing baseline plasma TFPI concentration in claudicants
undergoing femoropopliteal PTA and relationship with restenosis. The box represents the
interquartile range and the horizontal line in the box being the median value. The whiskers
represent the range of the data. The baseline TFPI levels were significantly higher in
those who developed restenosis following PTA than those who did not (p=0.05, Mann-
Whitney U test).
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Table 17. The difference of TFPI concentrations from pre angioplasty TFPI levels at
follow up intervals follwing PTA.
Negative mean
rank
Positve mean
rank
P (Wilcoxon
sign rank test)
Day1 Patent
Restenosis
3.00
2.00
3.00
2.59
0.6
0.59
Month 1 Patent
Restenosis
2.00
3.50
5.00
2.00
0.04
0.28
Month 3 Patent
Restenosis
1.00
1.00
3.50
2.50
0.08
0.28
Month 6 Patent
Restenosis
2.00
2.00
3.40
2.23
0.14
0.10
Wilcoxon sign rank test based on ranking the difference between baseline (pre PTA)
plasma TFPI and TFPI levels at different time points following PTA. Calculations
performed separately for the groups who remained patent and the ones who developed
restenosis. The difference of TFPI concentrations at followup intervals from the
baseline levels in either of the groups were not found to be statistically significant
(p>0.05, Wilcoxon’s sign rank test) except the borderline significance at month1
following PTA for the group who did not develop restenosis.
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3.2.11. Plasma TF/ TFPI ratio and restenosis following femoropopliteal PTA.
The ratio of baseline plasma TF and TFPI was found to be raised significantly (p=0.04;
Mann Whitney U) in claudicants who developed restenosis [median 0.12 (0.02- 0.89)]
than those whose angioplasty site remained patent [median 0.02 (0.01-0.07)]-Figure 16.
Following PTA, although the sample median TF/TFPI ratio was higher for the restenosis
group at day 1, month 3 and month 6, and was lower for the restenosis group at month 1,
the group differences did not reach statistical significance at all time points (p>0.05;
Mann Whitney U)-Table 18.
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Figure 16. Baseline (Pre PTA) plasma TF/TFPI ratio and restenosis following
femoropopliteal PTA
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Box and whisker plot showing baseline plasma TF/TFPI ratio in claudicants
undergoing femoropopliteal PTA and relationship with restenosis. The box
represents the interquartile range (IQR) and the horizontal line in the box being
the median value. The whiskers represent the range of the data. The baseline
TF/TFPI ratio was significantly higher in those who developed restenosis
following PTA (p=0.04; Mann Whitney U test).
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Table18. Plasma TF/ TFPI ratio and restenosis following femoropopliteal PTA
Median TFTFPI
ratio (interquartile
range)
Mean rank p (Mann Whitney U)
PRE PTA
Patent 0.02 (0.01-0.07) 14.40 0.04
Restenosis 0.12 (0.02-0.89) 22.67
DAY1
Patent 0.018 (0.004-0.07) 11.50 0.4
Restenosis 0.110 (0.005-0.320) 13.90
MONTH 1
Patent 0.015 (0.003-0.043) 10.79 0.8
Restenosis 0.003 (0.002-0.63) 11.43
MONTH 3
Patent 0.010 (0.004-0.02) 9.36 0.08
Restenosis 0.046 (0.006-0.623) 14.29
MONTH 6
Patent 0.009 (0.002-0.01) 9.21 0.06
Restenosis 0.047 (0.005-0.64) 14.57
The table shows significant association of baseline TF/TFPI ratio with restenosis
following PTA (p<0.05, Mann Whitney U). Although the post PTA plasma TF/TFPI ratio
were found to be higher at day 1, month 3 and month 6 and lower at month 1 for the
restenosis group, the group differences did not reach statistical significance (p> 0.05,
Mann Whitney U).
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Chapter 4. Discussion and Conclusions
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DISCUSSION
This study assessed two groups of patients: the first group were evaluated for changes in
symptoms whilst on a National Health Service waiting list for angioplasty (Clinical study)
and in the second group the role of TF and its natural inhibitor TFPI was assessed in
relationship to the development of restenosis after a technically successful percutaneous
balloon angioplasty of the index lesion (Laboratory study).
Clinical study
The first part of the study reassessed claudicants who had been awaiting angioplasty for
more than three months. Fifteen percent of the patients deteriorated clinically, but none
required urgent intervention to prevent limb loss.
Published literature on natural history studies and trials of conservative management of
claudicants suggests a relatively benign lower extremity outcome (Cox, Hertzer et al.
1993; Dormandy, Heeck et al. 1999; Amighi, Sabeti et al. 2004; Norgren, Hiatt et al.
2007). The finding of our study correlates well with these studies despite the fact that the
patients in our study were symptomatically severe at baseline and warranted PTA. This
symptomatic stabilization may be due to development of collaterals, metabolic adaptation
of ischaemic muscle, or the preferential alteration of gait by the claudicants to favour
non-ischemic muscle groups (Norgren, Hiatt et al. 2007). Only 19% of the patients
showed disease progression on duplex ultrasound at reassessment. We found no
association between disease progression and symptomatic deterioration in our patient
cohort. This data is consistent with previously published literature suggesting lack of
association between atherosclerotic disease progression and symptomatic deterioration in
claudicants (Da Silva, Widmer et al. 1979). The ABPI and reported maximum walking
distance showed an expected increase in the patients who improved symptomatically. The
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ABPI in clinically stable patients and those with deterioration of symptoms did not show
substantial change despite significant reduction in reported maximum walking distance. In
the group which showed deterioration, this finding does not support previous reports
suggesting significant correlation between ABPI and walking distance (McDermott,
Mehta et al. 1999; McDermott, Greenland et al. 2002). The lack of change in ABPI in this
group suggests that disease progression may not be the most important factor in the
observed decline in walking distance. This may be explained by the influence of atypical
exertional leg pain, produced by other co morbid conditions that may have contributed
additional effect on intermittent claudication. A wide range of leg symptoms other than
that of intermittent claudication in peripheral arterial disease has been reported in
published studies (McDermott, Mehta et al. 1999; McDermott, Greenland et al. 2001).
McDermott and SS Mehta reported a prevalence of 28.5% intermittent claudication,
56.2% atypical leg symptoms and absence of exertional pain in 15.3% of patients with
PAD identified by ankle-brachial index screening. Similarly, McDermott and Greenland
et al reported wide range of leg symptoms in patients with PAD. They have suggested
Comorbid diseases particularly diabetes and the presence of associated spinal stenosis
may contribute to atypical symptoms in patients with PAD.
As a result of the study, we identified claudicants with symptom change, and have been
able to prioritize patients with progression of symptom for early endovascular
intervention. Similarly, patients with improved symptom were managed conservatively
instead of PTA resulting in reduction in the non-urgent waiting time for femoropopliteal
PTA.
Nevertheless this study had certain weaknesses. Firstly, the lack of data on objective
measure of walking distance at baseline restricted us to compare patient reported walking
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distance at baseline and reassessment. Although symptoms reported by patients and
impairment of lifestyle are considered most important factor for considering
revascularisation, there is lack of correlation between symptoms and objective measure of
walking distance (McDermott, Mehta et al. 1999). Secondly, lack of objective data on
regular physical training by these patients during the waiting period may allow a bias in
comparing the outcomes (Menard, Smith et al. 2004). Thirdly, the true interval to
reassessment varied. We therefore can not make a definite recommendation as to the best
time for reassessment of patients on a waiting list. Finally, a significant proportion of our
patients could not tolerate treadmill test at reassessment due to shortness of breath,
arthritis or inability to walk at 2 miles per hour. Other tests including long distance
corridor walk and 6 minute walk work (Simonsick, Montgomery et al. 2001; Carter,
Holiday et al. 2003) may be useful for such cases.
In summary, findings in this part of study suggests
 Majority of patients with intermittent claudication remains symptomatically
stable over a period of time while waiting for angioplasty. Some of the
claudicants however symptomatically improve with time and their symptoms
correlate well with the ankle brachial pressure index.
 Symptomatic deterioration occurs in some claudicants without clinical
correlation with ABPI, suggesting possible presence of atypical leg symptoms.
Laboratory study
The second part of the study involved restenosis following femoropopliteal PTA and
association with plasma TF and TFPI.
Restenosis following femoropopliteal PTA is a major therapeutic problem, limiting the
long term efficacy of the procedure despite a high initial success rate. The technical success
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rate of the femoropopliteal PTA in this study was 94.3% which is similar to other
published figures (Karch, Mattos et al. 2000; Lofberg, Karacagil et al. 2001). Inability to
cross the lesions was the cause of technical failure in all cases in this study. The overall
restenosis rate at 6 months following femoropopliteal PTA was 32% which correlates well
with the previously published reports (Johnston 1992; Koppensteiner, Spring et al. 2006).
In our study, majority of the claudicants had either a TASC A or B lesion with 27%
having TASC C lesions. The incidence of restenosis was higher in TASC C lesion
although no significant difference in restenosis rate was found between TASC A and B
lesions. Previously published literature suggests TASC classification of femoropopliteal
lesion may be reliable predictor of patency following PTA. TASC C and D lesions are
reported to be associated with increased incidence of failure and re occlusion following
PTA (Surowiec, Davies et al. 2005; Conrad, Cambria et al. 2006).
Ninety six percent of the claudicants who had successful PTA had early haemodynamic
success at 24 hour following PTA as assessed by ankle-brachial pressure index. However
40% amongst them were found to have haemodynamic failure at follow-up assessments.
The haemodynamic failure following PTA did not correlate with the occurrence of
restenosis as identified by duplex ultrasound scan. Similar observations have been reported
in other studies. Nyamekye et al compared duplex assessment and ABPI with angiography
for surveillance of femoropopliteal lesions following PTA. The resting and post exercise
ABPI did not correlate with colour duplex assessment or formal angiogram in detecting
restenosis (Nyamekye, Sommerville et al. 1996). Golledge et al assessed patient symptom,
duplex assessment and ABPI measurement following femoropopliteal PTA; They found no
correlation between anatomical assessment using duplex USS and ABPI in detection of
restenosis (Golledge, Ferguson et al. 1999).
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Our study prospectively identifies an association between plasma TF and TFPI
concentrations with development of restenosis in claudicants undergoing
femoropopliteal PTA. TF is a transmembrane glycoprotein that is constitutively
expressed in adventitial and medial cells of blood vessel, and acts as a cofactor for
clotting factor VIIa following disruption of endothelial layer such as during angioplasty.
Neither peripheral blood cells nor endothelial cells express TF under normal conditions
(Moons, Levi et al. 2002). TF synthesis however can be induced in peripheral blood cells
under certain pathologic circumstances including sepsis, renal impairment, myocardial or
cerebro vascular events and malignancy (Donati MB 1984; G.C. Price 2004). In this
study we were able to rule out changes of TF due to these causes by our exclusion
criteria. Increased level of circulating TF activity has also been reported to be
associated with diabetes mellitus, hyperlipidemia and smoking (Sambola, Osende et al.
2003). Smoking, hyperlipidaemia and diabetes may have an implication in our study
group, as 57% of our study cohort were smokers while 35% were hyperlipidaemic and
14% being diabetic. However our small study was not powered to explore these
associations.
Our study detected tissue factor in the plasma of both healthy controls and the claudicants.
Presence of TF antigen in the peripheral blood of healthy individuals are also
documented in studies by Koyama et al and Abrecht et al. (Koyama 1994; Abrecht 1996).
The TF in the peripheral blood may be derived from circulating leucocytes, platelets or
may be associated with micro particles (Mackman 2006). Micro particles are exocytotic
products of plasma membrane and are supposed to originate preferentially from platelets.
In response to vascular injury in vivo, micro particles are rapidly recruited to the
injury site, triggering a TF dependent coagulation pathway (Falati 2003). No published
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literature has clarified the relative proportions of TF in monocytes, platelets and micro
particles in health and diseased states. Since our assay measures the TF concentration in
the plasma, one possibility is that we may have detected the micro particle associated
TF in the patient population.
We found plasma TF and TFPI levels to be significantly higher in claudicants than in the
healthy control group. Blann et al reported a similar result of increased plasma TF levels
in patients with peripheral arterial disease as compared to healthy subjects (Andrew D.
Blann 2000). Gorsk-Bierska et al also reported higher level of tissue factor in 62 patients
with intermittent claudication compared with healthy controls (Gosk-Bierska, Wysokin
Ski et al. 2008).
We found significant association of high plasma level of TF in claudicants who
developed restenosis following femoropopliteal PTA. The study shows that the
association of restenosis with increased plasma TF concentrations predates the angioplasty
and therefore cannot be procedure related. Previous studies have demonstrated an
association between circulating TF and restenosis after coronary revascularization
(Marcucci, Prisco et al. 2000; Mizuno, Ikeda et al. 2001; Tutar, Ozcan et al. 2003).
Mizuno et al demonstrated correlation between elevated levels of TF antigen in the
coronary sinus blood after coronary angioplasty and late restenosis (Mizuno, Ikeda et al.
2001). Tutar et al similarly demonstrated similar association of raised whole blood TF
activity with development of restenosis in 61 patients with stable angina undergoing
coronary angioplasty (Tutar, Ozcan et al. 2003). A study by Wahlgren et al failed to show
any association between TF and restenosis after PTA, although 29 of the 34 patients
underwent iliac angioplasty and the restenosis rate was extremely low (Wahlgren, Sten-
Linder et al. 2006). Our present study not only extends these observations in peripheral
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angioplasty but also examines the change in plasma TF levels following PTA over a
period of time. We found significantly raised plasma TF levels at 24 hour, 3 month and 6
months following PTA in claudicants who developed restenosis compared to those who
remained patent. At 1 month following PTA, the median plasma TF level was higher in
the restenosis group, but this was not statistically significant. This finding at present
remains unexplained but may involve complex interaction at cellular level following
angioplasty related trauma. However the study findings show a prolonged augmentation
of plasma TF level following the angioplasty in patients who developed restenosis. This
may suggest that prolonged up regulation of TF following the arterial injury may be
associated with the development of restenosis. Although the exact mechanism of influence
of TF in restenosis is unknown, it could be possible that higher levels of TF are deposited at
the injured or angioplasty site, promoting release of growth factors and inducing vascular
smooth muscle cell proliferation and migration. These are both important in formation of
neointimal hyperplasia.
The study also identified an increased concentration of baseline (Pre PTA) TFPI in
claudicants who developed restenosis following femoropopliteal PTA.
TFPI is a multivalent kunitz type protease inhibitor and produces FXa dependent
feedback inhibition of TF-FVIIa complex. (Broze 2003). TFPI is thought to be
distributed in three pools in vivo; 80-85% in endothelial cell surface, 10% in plasma and
3% in platelets (Bajaj, Birktoft et al. 2001). The endothelium bound TFPI is thought to
contribute towards maintaining the vessel lumen in antithrombotic state. Increased plasma
levels of TFPI thus may reflect endothelial injury. Increased plasma concentration of TFPI
has been reported in patients with ischemic heart disease (Moor, Hamsten et al. 1994;
Falciani, Gori et al. 1998; Soejima, Ogawa et al. 1999).
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The finding of raised baseline TFPI concentration in patients developing restenosis
following PTA does not correlate with experimental studies that have shown the role
TFPI in reducing restenosis following PTA (Brown, Kania et al. 1996; Sato, Asada et al.
1996). On analyzing the TF/TFPI ratio, the claudicants who developed restenosis showed
significantly higher baseline TF/TFPI ratio as compared to those whose angioplasty site
remained patent following femoropopliteal PTA. A raised TF/TFPI ratio indicates a
relative over activity of TF which may play important role in the development of
restenosis. This finding suggests that it may be the relative imbalance of TF and TFPI
which is more important in predicting restenosis than the absolute values of plasma TF or
TFPI levels. Following femoropopliteal the TFPI concentrations were found to be lower at
all the follow-up intervals in patients who developed restenosis as compared to those who
did not. This may indicate a relative augmented TF activity compared to that TFPI following
PTA in claudicants who developed restenosis. Our present study does not contribute to
understanding this assumption and further research is needed in this area.
Although this study demonstrates association between increased plasma TF with
subsequent development of restenosis, they do not establish causality. Indeed it is
possible that a significant fraction of TF may have been released from the
atherosclerotic plaque, which is known to be rich in micro particle associated TF
(Moons, Levi et al. 2002). In that case, raised level of plasma TF may represent a marker
of more extensive atherosclerotic disease which may be the true risk factor for the
development of restenosis. Only unilateral claudicants were taken in this study who may
have disease in the contra lateral limb without symptom. The diseased asymptomatic limb
may also contribute towards higher values of TF concentration.
Despite the above-mentioned limitation it is seems clear that an augmented TF
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concentration may relate to the development of restenosis. The study also suggests this
augmentation of TF may be to an extent related to a TF/ TFPI imbalance. Further studies are
needed to understand the TF/TFPI interaction in the development of restenosis.
In summary, findings in this part of study suggests
 There is a significant incidence of restenosis in claudicants following
femoropopliteal PTA.
 Plasma TF and TFPI levels in claudicants are higher compared to healthy
controls indicating their association with peripheral arterial disease.
 High plasma levels of TF or an imbalance of TF-TFPI may be associated with
occurrence of restenosis following angioplasty.
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CONCLUSIONS
1. Claudicants awaiting PTA may experience a change in symptomatology with time
which might alter management decisions. In units with a long waiting list, patients should
be reassessed in the clinic to review symptom and evidence of disease progression or
regression.
2. Increased plasma TF concentration is associated with restenosis following PTA;
however it is more likely that an altered TF/TFPI balance could be involved in the
occurrence of restenosis.
Further studies are necessary to evaluate relationship between specific mechanisms in the
development of restenosis and complex TF- TFPI interactions in peripheral arterial
disease.
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6.1. Protocol for preparation of reagents required in TF measurement
1. Coating Buffer: 50 mM Carbonate
1.59g of Na2CO3 and 2.93g of NaHCO3 made up to 1 litre. pH adjusted to 9.6 and
stored at 2-8 0C maximum up to 1 month.
2. PBS: (base for wash buffer and Blocking buffer) - 8.0g NaCl, 1.1 5g Na2HPO4, 0.2g
KH2PO4 and 0.2g KCl, made up to 1 litre. pH adjusted to 7.4 and stored up to 1 month
at2- 80C.
3. Wash Buffer: PBS-Tween (0.1%, v/v)
1.0 mlof Tween-20 was added to 1 litre of PBS. pH is adjusted to 7.4 and stored at 2- 80C
up to 1 week.
4. Blocking Buffer: PBS-BSA (2%, w/v)
5.0 g of Bovine Serum Albumin (Sigma-RIA grade) was dissolved in 200 ml of PBS.
The pH adjusted to 7.4, if required. Volume was made up to 250 ml with PBS and and
stored frozen in aliquots at -200C.
5. Sample Diluent: HBS-TX100
5.95g HEPES (free acid) and 1.46 g NaCl dissolved in 200 ml H2O. 0.25 ml of Triton
X-100 was then added and pH adjusted to 7.2 with NaOH. The final volume of 250 ml was
made by adding H2O. The diluent then stored frozen in aliquots at -200C.
6. Conjugate Diluent: HBS-BSA-T20
5.95g HEPES (free acid), 1.46 g NaCl, 2.5 g Bovine Serum Albumin (Sigma, RIA grade)
dissolved in 200 ml H2O. 0.25 ml of Tween-20 was then added and pH adjusted to 7.2 with
NaOH. The final volume of 250 ml was made by adding H2O. The diluent then stored
frozen in aliquots at -200C.
7. Substrate Buffer: Citrate-Phosphate buffer pH 5.0
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2.6g Citric acid and 6.9g Na2HPO4 made up to a final volume of 500 ml with purified
H2O and stored at 2-80C up to 1 month.
8. OPD Substrate: (o- Phenylenediamine.2HCl (5mg tablets: Sigma # P-6912). Made up
immediately before use. 5 mg OPD was dissolved in 12 ml substrate buffer and then 12 μl
30% H2O2 was added.
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6.2. Protocol for preparation of reagents required in TFPI measurement
A. Standards
1. 0.5 mL of cold (2-8°C) distilled H2O was added to the TFPI Depleted Plasma vial.
The vial was allowed to stand on ice for 2-3 minutes.
2. A solution of 5% TFPI depleted plasma was then prepared by diluting the TFPI depleted
plasma 1:20 with Sample Buffer. The solution was let stand for 5 minutes after gentle
mixing.
3. 1 mL of the 5% TFPI depleted plasma was added to the 5 ng/mL TFPI standard vial.
4. Standards of 2.5, 1.25, 0.625 and 0.3 12 ng/mL concentration were generated by serially
diluting the 5 ng/mL TFPI plasma standard. Tubes were labelled and 0.5 mL of 5% TFPI
depleted plasma was pipetted into each tube. 0.5 mL of the 5 ng/mL TFPI plasma standard
was then added into the 2.5 ng/mL labelled tube and mixed. 0.5 mL was then transferred
from the 2.5 ng/mL tube into the 1.25 ng/mL labelled tubes and mixed. Same process was
continued for the 0.625 ng/mL and 0.3 12 ng/mL labelled tubes.
5. 5% TFPI depleted plasma was used as the "0" standard.
B. TFPI Reference Plasma
0.5 mL of cold filtered deionised H2O was added to the vial and gently mixed for 2
minutes.
C. Detection Antibody
5.5 mL filtered deionised H2O was added per vial and mixed gently for 3 minutes.
D. Enzyme Conjugate Diluent
20 mL filtered deionised H2O was added to the vial and mixed well.
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E. Wash Buffer
The content of PBS packet was dissolved in 900 mL of filtered deionised H2O, Mixed well
and diluted to a final volume of 1 litre with filtered deionised H2O
F. Sample Buffer
Appropriate amount of Sample Buffer was prepared by adding BSA to Wash Buffer to a
final concentration of 1% w/v (1 gmBSA/100 mL Wash Buffer).
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6.3. Patient information leaflet
Thank you for reading this
Study Title:
The influence of plasma Tissue factor and Tissue factor pathway inhibitor concentration in
restenosis following femoro popliteal percutaneous transluminal angioplasty.
Invitation:
You are invited to take part in a research study. Before you decide it is important for you
to understand why the research is being done and what it will involve. Please take time to
read the following information carefully and discuss it with friends, relatives
and your GP if you wish. Ask us if there is anything that is not clear or if you would like more
information. Take time to decide whether or not you wish to take part.
What is the purpose of the study and why have I been chosen?
You have been chosen to be a part of the study because you do not suffer from poor leg
circulation caused by narrowing in the arteries supplying blood to your leg. Certain
people suffer from poor leg circulation due to narrowing in the arteries supplying blood to
their leg. This condition may be treated by balloon “angioplasty” to widen narrowed part of
the artery. The initial result of this procedure is usually very good and will gives prompt relief
from symptoms. A significant number of people may develop repeat narrowing of their
arteries over a period of time (20%-40% at 1 year, 50% at 3yr and approximately 60% at 5
year according to published literature) and may require repeat angioplasty. We know there
are certain protein substances in the blood, which are involved in repeat narrowing of the
arteries. Early detection of these substances may help in identifying the problem early.
In future it may also be possible to modify the action of this substances to prevent re-
narrowing of the arteries.
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The main aim of this study is to define the link between these substances and repeat
narrowing of the leg arteries following angioplasty. It is also important to compare the
blood level of these substances in healthy person and people with poor leg circulation to
know if these are present only in patients with poor leg circulation. As you do not suffer
from this condition you are suitable being a healthy control for this study.
Do I have to take part?
It is up to you to decide whether or not to take part. If you do decide to take part you will
be given this information sheet to keep and be asked to sign a consent form. If you decide
to take part you are still free to withdraw at any time without giving a reason. This will
not affect the standard of care you receive.
What will happen to me if I take part?
If you agree to take part in the study, you will be asked to sign a consent form after
discussion regarding the nature of the study. You will then have a blood sample
collected by needle puncture.
What do I have to do?
No extra demands will be made of you apart from taking blood samples from you.
Do I have to take part?
Only if you want to. Participation is voluntary, you may refuse to participate or
withdraw from the study at any time. You do not need to tell us why you do not want to
take part.
Are there any risks involved?
Essentially there are no side effects or disadvantage of participating in this study. The
potential benefit of the study is that we may be able find factors, which are in someway
responsible for repeat narrowing of arteries following angioplasty. The information we
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get from this study may help us to treat future patients with narrowing of leg arteries
better.
Are there any costs involved?
There is no cost involved on your part for being a part of the study.
Confidentiality
In order to meet legal obligations, a member of the of the department of vascular
surgery, academic vascular surgery unit, Hull Royal Infirmary may inspect your
hospital records. Details of your treatment and your past relevant medical history as
required for the study, will be recorded on a Case Record Form (CRF) the information
from which will be entered onto computer in the Department of Vascular Surgery, Hull
Royal Infirmary. A CRF includes all information collected in the course of the research
study. This information will be retained by the Department of Vascular Surgery and may
be passed on to the authorized regulatory authorities. The records will identify you only by
a number (not your hospital number) and your initials. All information in your notes and
CRF will be treated in strict confidence. A copy of this Informed Consent Form will be
kept with the CRF and you will be given a copy. The information from this study will be
retained until the data are analyzed for two years in the Department of Vascular Surgery,
Hull Royal Infirmary.
By signing the attached consent form you give permission for the above to occur.
If you agree to participate in this study, your General Practitioner will be informed,
unless you state otherwise.
Your rights
Your participation in this study is entirely voluntary and refusal will not affect any other
medical treatment. You may, without giving reason, refuse to take part in the trial, and
this will not in any way affect your continuing treatment by your doctor. Your doctor will
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give you any relevant updated information about any relevant updated information about
further plan of instituting any treatment or investigation that may occur during the study.
Who is organising and funding the research?
This study is organised by the Academic Vascular Unit at Hull Royal Infirmary and
funded by grants that it receives.
Trial-related injury
If taking part in this research project harms you, there are no special compensation
arrangements. If you are harmed due to someone's negligence, then you may have
grounds for legal action but may have to pay for it. Regardless of this, if you wish to
complain about any aspect of the way you have been approached or treated during the
course of this study, the normal National Health Service complaints mechanisms will be
available to you.
Thank you for taking the time to read this information sheet and consenting to
participate in the study. You will be given a copy of this information sheet and a copy of
your consent to participate form. If you have any further queries or questions please don’t
hesitate to contact:
Mr Biswajit Ray FRCS.
Clinical Research Fellow
Vascular Laboratory, Hull Royal Infirmary, Hull HU3 2JZ.
Tel:01482674178.
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6.4. Consent Form
March 2003
Study number:
Patient ID number:
Title of project:
Plasma tissue factor, tissue factor pathway inhibitor and restenosis following
femoropopliteal percutaneous transluminal angioplasty in claudicants
Invitation:
Names of researchers:
Mr. Biswajit Ray FRCS. Research Fellow in Vascular Surgery, the University of Hull
Mr IC Chetter MBChB FRCS. Lecturer in Vascular Surgery, the University of Hull.
Dr C Ettelaie, Lecturer, Department of Biological Sciences, the University of Hull
Prof. PT McCollum MCh, FRCS. Professor of Vascular Surgery, the University of Hull
Contact Address: Telephone No: 01482 674178
Academic Vascular Unit
Anlaby Alderson House, Hull Royal Infirmary Fax No: 01482 675665
Road, Hull HU3 2JZ Please initial
1. I confirm that I have read and understood the information sheet dated February
2003 for the above study and have had the opportunity to ask questions
2. I understand that my participation is voluntary and that I am free to withdraw at any
time, without giving any reason, without my medical care or legal rights being affected
3. I understand that sections of any of my medical notes may be looked at by
responsible individuals where it is relevant to my taking part in research. I
give permission for these individuals to have access to my records.
4. I agree to take part in the above study
Name of patient Date Signature
Name of person taking consent Date Signature
Researcher Date Signature
1 for patient, 1 for researcher, 1 to be kept with hospital notes
February 2003
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6.5. Letter to patient`s GP
Date
Dear Dr.
Re: <Patient Name and Address>.
“Plasma tissue factor, tissue factor pathway inhibitor and restenosis
following femoropopliteal percutaneous transluminal angioplasty in claudicants”
I am writing to inform you that your patient has been enrolled into the above research study.
The purpose of the study is to evaluate the role of above named substances in the blood and
restenosis following angioplasty of femoropopliteal arteries.
The subject consented for blood samples being taken for the above study before and after
undergoing angioplasty. Follow-up will be arranged at 3 months and 6 months at the Academic
vascular surgical unit, during which time, subject will undergo blood sampling, ABPI
measurement and Doppler USG assessment of angioplastied artery. The clinical implications of
this study will be to possibly identify restenosis following angioplasty at an early stage by
detecting these substances early. In future it may also be possible to modify the action of
these substances to prevent re-narrowing of the arteries. If you have any questions regarding
any of the above, please feel free to contact me on 01482 674178.
Yours sincerely
Mr B.Ray FRCS
Research Fellow, Vascular Surgery
Vascular Laboratory, Alderson House
Hull Royal Infirmary
Hull, HU3 2 JZ.
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6.6. List of abbreviations
ABPI Ankle: brachial pressure indexe
ACE Acetyl coenzyme
ANOVA Analysis of variance
AT-I Angiotensin type I receptor
BSA Bovine Serum Albumin
0C Degree Celcius
CAD Coronary artery disease
COPD Chronic obstructive pulmonary disease
ECM Extracellular matrix
ELISA Enzyme linked immunosorbent assay
FGF-2 Fibroblast growth factor-2
FXa Activated factor Xa
g Gram
H2O Water
H2 SO4 Sulphuric acid
HEPES N-(2-Hydroxyethyl)piperazine-N' -(2-ethanesulfonic acid)
HRP horseradish peroxidase
IHD Ischemic heart disease
IQR interquartile range
K1,2,3 Kunitz domain1,2,3
kDa killodalton
KH2PO4 Potassium biphosphate
LDL Low density lipoprotein
M:F Male to female ratio
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MAPKs Mitogen activated protein kinases
MI Myocardial infarction
ml Millilitre
MMP Matrix metalloproteinase
MRA Magnetic resonance angiogram
Na2CO3 Sodium carbonate
Na2HPO4 Sodium biphosphate
NaCl Sodium chloride
NaHCO3 Sodium bicarbonate
NaOH Sodium hydroxide
ng Nanogram
NHS National health services
nm Nanometre
OPD o-phenylenediamine
PAD Peripheral arterial disease
PARS Protease activated receptors
PBS Phosphate buffer solution
PDGF Platelet derived growth factors
POP Popliteal artery
PRIME Prospective Epidemiological study of Myocardial
Infarction
PTA Percutaneous transluminal angioplasty
PTCA Percutaneous transluminal coronary angioplasty
RPM Revolution per minute
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SFA Superficial femoral artery
T-20 Tween 20
TASC Transatlantic Inter-Society Consensus
TF Tissue factor
TF-EIA-C Capture antibody for tissue factor
TF-EIA-D Detecting antibody for tissue factor
TFPI Tissue factor pathway inhibitor
TGF-β Transforming growth factor- β
TMB 3,3’ ,5,5 ’-Tetramethylbenzidine
TPT Tibio peroneal trunk
VSMC Vascular smooth muscle cell
μl Microlitre
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6.7. Publications and Presentations arising from the thesis
Plasma tissue factor is a predictor for restenosis after femoropopliteal angioplasty Br J
Surg. 2007 Sep;94(9):1092-5.
- Original article
Presentations to learned societies and published abstracts
1. Plasma tissue factor, a predictor for restenosis following percutaneous transluminal
angioplasty (PTA).
Published in abstract form in BJS Volume 92, Number 4, April 2005, p 502
2. “Prognostic implication of plasma tissue factor (TF) and tissue factor pathway
inhibitor (TFPI) in restenosis following percutaneous transluminal angioplasty (PTA)”-
Society ofAcademic and Research Surgery, Edinburgh, January 2006.
Published in abstract form in BJS Volume 93 Issue S3, Pages 1 - 57 (July 2006)
3. "Restenosis following femoropopliteal percutaneous transluminal angioplasty is predicted
by plasma tissue factor "– 15th Annual Winter Meeting of the Peripheral Vascular Surgery
Society, Steamboat Springs, Colorado, January, 2005.
4. “Impact of reassessment on a waiting list for percutaneous transluminal angioplasty
(PTA). 12th International Conference ofEuropean Association ofEndoscopic Surgeons,
Barcelona, June 2004.
